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1. SUMMARY 
Sepsis is one of the most common diseases on intensive care units all over the 
world and accounts there for the highest mortality rate. One of the hallmarks of 
sepsis is an accelerated T-cell apoptosis, resulting in a compromised immune 
state with the inability to eradicate pathogens. This promotes organ damage or 
even organ failure. A multiple organ dysfunction evolves, which often ends up in 
septic shock and death. Recently, it was shown that severe T-cell depletion 
correlates with sepsis mortality. When inhibiting T-cell apoptosis, an increased 
mouse survival was observed in experimental sepsis. 
One factor that plays a potential role during sepsis is the ligand-activated 
transcription factor peroxisome-proliferator activated receptor  (PPAR). 
Besides its transcriptional activity PPAR confers the ability to repress other 
transcription factors and to reduce pro-inflammatory cytokine expression. In the 
context of sepsis, PPAR is upregulated in T-cells derived from septic patients 
and a PPAR ligand was identified in septic patient’s serum. Furthermore, 
applying PPAR agonists to activated T-cells provokes their apoptosis. The 
present thesis appoints PPAR to be responsible for T-cell death during sepsis 
and introduces PPAR as a potential target to achieve protection against the 
deleterious consequences of T-cell depletion. 
The first aim of my thesis was to discover the role of PPAR in T-cells during 
non-lethal endotoxemia. When injecting 1 mg/kg lipopolysaccharide (LPS) to 
wild type mice (WT) and mice bearing a conditional depletion of PPAR in T-
cells (Tc-PPAR
-/-),
 a massive depletion of WT T-cells was observed, whereas 
no T-cells were depleted in the Tc-PPAR
-/- population. In these experiments, I 
identified the pro-survival cytokine IL-2 as highly important for T-cell survival by 
initiating anti-apoptotic Bcl-2 signaling. Although the LPS-model induces a 
systemic inflammation it is not very similar to human sepsis. Therefore, I made 
use of a polymicrobial sepsis model that mimics a ruptured appendicitis, the 
cecum ligation and puncture model (CLP). Analyzing T-cell counts thereafter 
demonstrated an abrogated T-cell depletion in the Tc-PPAR
-/- group. 
Furthermore, high T-cell counts of Tc-PPAR
-/- mice correlated with significantly SUMMARY     2 
higher survival rates after CLP-sepsis, accompanied by an improved bacterial 
clearance and less end organ damage. Pathway analyses identified high IL-2 
and anti-apoptotic Bcl-2 expression levels in Tc-PPAR
-/- T-cells, confering 
reduced T-cell apoptosis. This pathway was corroborated by experiments 
limiting the pro-survival effects of Tc-PPAR
-/- mice by using an   
IL-2 neutralizing antibody. This setup reduced Bcl-2 expression and provoked 
apoptosis resulting in lower T-cell counts and a higher mortality rate. Secondly, I 
identified PPAR-induced PTEN expression to counteract the pro-survival 
PI3K/Akt pathway and induce pro-apoptotic Bim expression. Next, I questioned 
whether PPAR displays a therapeutic target that could be modified by synthetic 
inhibitors, such as the specific, irreversible antagonist GW9662. I confirmed the 
potential of GW9662 to inhibit PPAR activity by using in vivo PPRE reporter 
analysis. Time kinetics for application of GW9662 resulted in an optimal timing 
regime when 1  mg/kg GW9662 was applied at 3  h following CLP. GW9662 
application provoked complete abrogation of T-cell depletion, even an increase 
of peripheral blood T-cells was observed. Again, a high T-cell count correlated 
to increased survival of the GW9662-treated population and was accompanied 
by improved bacterial clearance and less end organ damage. In order to identify 
which T-cell subpopulation (CD4
+ or CD8
+) is responsible for survival and to 
determine the optimal time frame to therapeutically applicate the inhibitor, 
3 mg/kg GW9662 was applied at 5 h after CLP. The dose of 1 mg/kg applied at 
5 h after CLP revealed no benefit. The higher dose provoked no depletion of the 
CD8
+ subpopulation, but CD4
+ T-cells were reduced to untreated control levels. 
Survival studies for 7  days resulted in a mortality rate of 50%, which is not 
significantly better than survival of control mice. This result proposes CD4
+ cells 
to promote survival and to correlate with a better outcome of sepsis. 
In conclusion, I identified PPAR to be crucial for T-cell apoptosis during sepsis 
by modifying two apoptosis pathways. In addition, I established pharmacological 
blocking of PPAR as an option to improve experimental sepsis and propose 
this treatment as possible target for sepsis therapy in humans. ZUSAMMENFASSUNG     3 
2. ZUSAMMENFASSUNG 
Sepsis ist eine der häufigsten Erkrankungen auf Intensivstationen weltweit und 
verursacht dort die höchste Mortalitätsrate. Ein besonderes Kennzeichen der 
Sepsis ist der rapide Verlust von T-Zellen durch Apoptose. Dies hemmt den 
Immunstatus des Patienten und bewirkt ein Unvermögen gegen Pathogene 
anzukämpfen. Eine Organdysfunktion oder sogar ein multiples Organversagen 
wird hervorgerufen. Die T-Zelldepletion korreliert mit der hohen Sepsismortlität 
und ihre Hemmung führte zu einem verbesserten Überleben in experimenteller 
Sepsis. 
Ein Faktor, der während der Sepsis eine wichtige Rolle spielt ist der Ligand-
aktivierte Trankriptionsfaktor Peroxisom Proliferator-aktivierter Rezeptor  
(PPAR). Neben seiner transkriptionellen Aktivität vermag PPAR andere 
Transkriptionsfaktoren zu binden und somit die Expression von 
proinflammatorischen Zytokinen zu inhibieren. PPAR ist in T-Zellen septischer 
Patienten induziert und die Zugabe eines PPAR Agonisten zu aktivierten T-
Zellen löst bei diesen Apoptose aus. Die vorliegende Arbeit identifiziert PPAR 
als verantwortliches Protein für die massive T-Zellapoptose während der Sepsis 
und definiert PPAR als potenzielles Target zur Hemmung der verhängnisvollen 
Konsequenzen der T-Zellapoptose septischer Patienten. 
Das erste Ziel meiner Arbeit war es, die Rolle von PPAR in T-Zellen während 
der nicht-letalen Endotoxinämie zu analysieren. Dafür verwendete ich Mäuse, 
die eine konditionelle Depletion von PPAR in T-Zellen (Tc-PPAR
-/-) aufweisen. 
Diesen und Wildtyp (WT) Mäusen wurde 1 mg/kg Lipopolysaccharid (LPS) 
verabreicht, das zu einer massiven Apoptose von WT T-Zellen jedoch nicht von 
Tc-PPAR
-/- T-Zellen führte. In WT T-Zellen hemmte PPAR die Expression des 
T-Zell-Überlebensfaktors IL-2 und verringerte dadurch die Expression von anti-
apoptotischem Bcl-2. Das LPS Modell imitiert zwar eine systemische 
Inflammation, jedoch wird mit diesem Modell keine Sepsis ausgelöst. Darum 
etablierte ich ein polymikrobielles Sepsismodell, das einen 
Blinddarmdurchbruch nachahmt, das Zökum Ligations- und Punktionsmodell 
(ZLP). Die Analyse der T-Zellzahl nach ZLP ergab ebenfalls eine Aufhebung ZUSAMMENFASSUNG     4 
der T-Zelldepletion in Tc-PPAR
-/- Mäusen. Zudem zeigten diese Mäuse ein 
signifikant verbessertes Überleben, das mit verstärkter Bakterienbeseitigung 
und weniger Organschäden korrelierte. Wiederrum war die T-Zell Apoptose 
durch induziertes IL-2 und Bcl-2 gehemmt. Dieser Signalweg wurde durch 
Versuche mit einem IL-2 neutralisierenden Antikörper bestätigt, der den 
Überlebensvorteil der Tc-PPAR
-/- Mäuse aufhob. Als nächstes untersuchte ich 
den PI3K/Akt Signalweg, der in meinem Modell durch PPAR-induziertes PTEN 
gehemmt wurde und die Expression von pro-apoptotischem Bim erwirkte. Um 
PPAR als therapeutisches Angriffsziel zu verifizieren verwendete ich den 
irreversibel bindenden, spezifischen Antagonist GW9662. Das Potenzial von 
GW9662 PPAR zu inhibieren bestätigte ich in in vivo Reporteranalysen. Durch 
die Applikation von 1 mg/kg GW9662 3 h nach ZLP wurde die T-Zelldepletion in 
WT Mäusen verhindert und es konnte sogar ein Anstieg der peripheren Blut-T-
Zellzahl festgestellt werden. Die hohe T-Zellzahl korrelierte auch in diesem 
Versuchsansatz mit einer hohen Überlebensrate, einer verbesserten 
Bakterienbeseitigung sowie weniger Organschäden. Zur Identifikation des T-
Zellsubtyps (CD4
+ oder CD8
+), der für das Überleben notwendig ist, sowie um 
das therapeutische Fenster genau zu etablieren, wurden Versuche mit einer 
GW9662-Dosis von 3 mg/kg appliziert nach 5 h ZLP durchgeführt, da die Dosis 
von 1 mg/kg gegeben nach 5 h ZLP in Vorversuchen keine Wirkung zeigte. Die 
höhere Dosis führte zu einer Vermehrung der CD8
+ T-Zellsubpopulation, jedoch 
zeigte sich eine starke Verringerung der CD4
+ Zellzahl. In diesem 
Versuchsansatz überlebten 50% der Mäuse. Dies stellte keinen signifikanten 
Überlebensvorteil im Vergleich zu den Kontrollen dar und identifiziert CD4
+ 
Zellen als überlebensnotwendig während der Sepsis-induzierten 
Immunsuppression. 
Zusammenfassend war es mir im Rahmen dieser Arbeit möglich PPAR als 
entscheidenden apoptose-auslösenden Faktor für T-Zellen herauszustellen und 
zwei durch PPAR modifizierte Apoptose-Signalwege zu identifizieren. Die 
pharmakologische Hemmung von PPAR konnte ich als Therapieoption 
während der experimentellen Sepsis identifizieren und damit einen potentiellen 
neuen Angriffspunkt im Rahmen der Sepsistherapie vorstellen. INTRODUCTION     5 
3. INTRODUCTION 
3.1. Sepsis 
3.1.1. History 
Though the term sepsis is linked closely to modern intensive care, the medical 
concept is rather older. The word sepsis has its origin with Hippokrates (~460-
370 BC), who suggested two forms of tissue breakdown: Pepsis as a process 
represented by fermentation of wine or the digestion of food. It was associated 
with life and good health; sepsis, on the contrary, described a process of 
deterioration and decay and was associated with death and disease. With the 
identification that microorganisms were the agents of deterioration, the word 
‘sepsis’ was applied to the clinical condition resulting from bacterial infection (1). 
In 1847 Ignaz Semmelweis (1818-1865) was the first researcher who developed 
a modern view of sepsis. He discovered that cases of puerperal fever, a form of 
sepsis, also known as childbed fever, could be decreased drastically if doctors 
washed their hands in a chlorine solution before gynaecological examinations. 
The result was that the mortality rate of women in childbed dropped from 35% 
to 1%. The French chemist Louis Pasteur (1827-1912) revealed that tiny single 
cell organisms caused putrefaction. He called them bacteria or microbes and 
correctly deducted that these mirobes could be causing diseases. In 1914, 
Hugo Schottmüller (1867-1937) paved the way for a modern definition of sepsis: 
“Sepsis is present if a focus has developed from which pathogenic bacteria, 
constantly or periodically, invade the blood stream in such a way that this 
causes subjective and objective symptoms”. Thus, for the first time, the source 
of infection as a cause of sepsis came into focus and the etiology and 
pathophysiology of sepsis became more and more clear. In 1989, Roger C. 
Bone (1941-1997) established a simple definition for sepsis syndrome, which 
was based on specific clinical symptoms and included a known source of 
infection that is still valid until today: “Sepsis is defined as an invasion of 
microorganisms and/or their toxins into the bloodstream, along with the 
organism´s reaction against the invasion” (2). INTRODUCTION     6 
3.1.2. Epidemiology  and  definition 
According to the “Kompetenznetzwerk Sepsis” (SepNet) sepsis provokes an 
annual incidence of 154,000 cases in Germany. Despite advances in critical 
care and antimicrobial therapy, the disease displays a mortality rate of 54% for 
septic shock and severe septic conditions, and 20% for sepsis (3) making the 
disease one of the most prevalent causes of death on intensive care units 
(ICUs). Even with intensive and successful investigations and promising 
preclinical treatment trials, so far efforts to reduce the mortality rate of sepsis in 
patients have failed. Increasing costs of critical care treatment exert pressure to 
better understand the molecular mechanisms of sepsis pathophysiology in order 
to generate new therapeutic strategies (4). 
One needs to differentiate between an infection (invasion of bacteria, viruses, 
funghi in the host) and a sepsis (response of the host to the infection). The 
clinical picture of “sepsis” can be devided into different phases: the systemic 
inflammatory response syndrome (SIRS), sepsis, severe sepsis, septic shock 
and multiple organ dysfunction syndrom (MODS) (6-7) (Table 1). 
While most of the patients survive the first SIRS with intensive medical care 
without developing MODS they might develop a compensatory anti-
inflammatory response syndrome (CARS). This state is characterized by a 
suppressed immunity with less possibility to fight the infections thus, being 
called immuneparalysis. If the primary infection is getting dominant again, or if a 
secondary infection arises, MODS might develop and eventually provokes 
death of the patient. 
Gram-positive or gram-negative bacteria mostly cause sepsis, but also funghi 
(especially candida infections), and less often viruses or parasites. Patients that 
are most prominent to develop a sepsis are old people, patients with metabolic 
or neoplastic diseases or immunedefficiency. Further, immunsuppressed 
patients i.e. after organ transplantation and those who rely on catheter or other 
invasive material (“plastic”) belong to high-risk patients (8-10). Parallel to the 
different sepsis states, a risk evaluation can be achieved by different laboratory 
parameters (oxygen consumption, arterial pH-value, sodium and potassium 
concentrations in serum, creatinin, hematokrit, bilirubin). Therefore, the 
APACHE (acute physiology and chronic health evaluation) III Score (9, 11) and INTRODUCTION     7 
the SOFA (Sepsis-related Organ Failure Assessment) Score (9, 12) were 
developed. 
 
Table 1: Clinical definition of sepsis (5). 
SIRS 
Systemic immune response to a non-infectious state, with at least two 
of the following parameters: 
Temperature               <36° or >38.3°C 
Heart rate               >90 beats/min 
Respiratory rate  >20 breaths/min or paCO2 < 32 mmHg 
White blood cell count   <3500 or >12,000 cells/ml 
or >10% immature band forms 
Sepsis 
Systemic response to infection, manifested by two or more of the 
conditions mentioned under SIRS (SIRS+evidence of infection) 
Severe sepsis 
Sepsis associated with organ dysfunction, hypoperfusion, or 
hypotension including lactic acidosis, oliguria, or acute alteration in 
mental state. 
Septic shock 
Sepsis-induced hypotension (e.g. systolic blood pressure <90 mmHg or 
a reduction of >40 mmHg from base line) despite adequate fluid 
resuscitation, along with the presence of perfusion abnormalities that 
may include lactic acidosis, oliguria, or an acute alteration in mental 
state. Vasopressor- or inotropic-treated patients may not be 
hypotensive at the time of measurement. 
MODS 
The presence of altered organ function in an acutely ill patient such that 
homeostasis cannot be maintained without intervention. 
 
3.1.3. Sepsis  pathophysiology 
Upon release of bacteria to the peritoneum, the immune system is confronted 
with bacteria specific antigen. First instance for defense is the innate immune 
system, the first recognition of bacterial pathogens. Local macrophages and 
granulocytes posses an evolutionary old repertoire of receptors (PRR=pattern 
recognition receptors), that recognize constant molecular patterns of microbial 
pathogen (such as LPS or peptidoglykanes), so called PAMPs (pathogen-
associated molecular patterns). Recognition of PAMPs provokes, on the one 
hand, an activation of the confronted cell (macrophages, granulocytes) that 
phagocytes the pathogens. On the other hand, a signal cascade in the nucleus INTRODUCTION     8 
is activated producing inflammatory cytokines and chemokines (i.e. IL-1, IL-6, 
IL-8, IL-12, TNF, RANTES) (9, 13-14). This secretion of inflammatory 
cytokines provokes an activation of surrounding innate immune cells and 
lateron activation of adaptive immune cells (local effects). Futhermore, 
cytokines induce systemic effects to activate the host against pathogens 
(systemic effects) (9, 15) (Table 2). 
 
Table 2: Local and systemic effects of cytokines released by innate immune cells (9, 
15). 
  Local effects  Systemic effects 
IL-1  Activates endothelium  Fever 
IL-6  Activates lymphocytes 
Promotes antibody production 
Fever 
Produces actue phase proteins 
IL-8  Chemotactic on leukocytes (neutrophils)   
IL-12  Activates NK-cells 
Differentiation of CD4
+ T-cells to Th1 cells   
TNF 
Activates endothelium 
promotes permeability of vessel wall 
Fever 
Shock 
Anergy 
 
Innate Immunity 
It is the goal of the organism to prevent infections as early, effective, and fast as 
possible to limit a generalisation and spreading throughout the body. To achieve 
this, numerous mediators that affect the endothelium of local blood vessels are 
released. Five cardinal signs characterize a typical clinical inflammation that is 
initiated by effects of mediators: rubor (redness), dolor (pain), calor (heat), 
tumor (swelling) and functio laesa (loss of function) (9). 
All innate immune cells derive from hematopoetic stem cells in the bone marrow 
that produce lymphatic or myeloid precursor cells. Cells of the innate immunity 
derive from myeloid precursors. These are granulocytes, also called 
polymorphnucleic leukocytes (PMN) that are further differentiated in neutrophils, 
eosinophils, basophils, and monocytes, which extravasate into tissue and are 
by then called macrophages. They form the first defensive front against invaded INTRODUCTION     9 
microorganisms. Approximatly 99% of all infections are eliminated by the innate 
immune system (8). 
The most important receptors of the innate immune system are CD14 and the 
Toll-like receptors (TLR). CD14 is a glycoprotein, which exists in 2 forms: 
membrane-bound and soluble (sCD14). The membrane-bound form is 
expressed on i.e. monocytes, macrophages, PMN, B-cells, and liver parenchym 
cells. The expression rate rises with maturation and contact with LPS. CD14 is 
not only the receptor for LPS, but also for other microbial ligands. The transfer 
of LPS to CD14 is catalysed by LBP (LPS-binding protein). LBP is an acute 
phase protein, which is secreted by the liver, the lung and the kidneys. IL-6 and 
IL-1 induce the production of LBP. CD14 is a glycosylphosphadidylinositol-fixed 
receptor without transmenbrane domain. Therefore, signal transduction is 
accomplished by another molecule, TLR4. TLR4 is a family member of the Toll-
like receptors (TLR). The TLR family consists of 10 family members so far 
(TLR1-10). The TLR belong to the TIR-superfamily that is characterized by a 
Toll/IL-1-receptor domain (TIR). TLR2-5 and TLR9 take part in recognizing 
microbial products, but differ in their ligands. TLR1 and TLR6 have modulatory 
functions. They do also differ in their expression patterns. The TLR have an 
important role in recognizing and differentiate between numerous microbial 
products (8). 
Upon recognition of microbial products phagocytes are activated. LPS-activated 
macrophages produce free oxygen radicals and other mediators (lysozym, 
kationic proteins, lactoferrin) with microbicidal potential. Furthermore, pro-
inflammatory cytokines are released (tumor necrosis factor  (TNF, IL-1, IL-6, 
IL-12, HMGB1), chemokines (MCP-1, IL-8, MIP-1 and ) as well as lipid 
mediators (platelet-activating factor (PAF), prostaglandins (PG), leukotriens) 
that modify the surrounding tissue (8). TNF is the key enzyme for 
inflammation, inducing the inducible nitric oxide (NO)-synthase (iNOS) and the 
release of NO, provoking a local vasodilatation. This results in higher, but 
slower blood flow (causing rubor and calor). Similar to TNF, the prostaglandin 
E2 (PGE2) is produced by products of cell membranes and further promotes 
vasodilatation. Microorganisms and LPS also turn on the humoral innate 
immune response. The complement system activates the membrane-activation INTRODUCTION     10 
complex (MAC) by cleaving the anaphylatoxins C5a and C3a. They in turn can 
induce degranulation of basophilic granulocytes and mast cells. Thereby 
released histamine, serotonin, and leukotriene B4 (LTB4) provoke pain (dolor) 
and further increase vasodilatation. Due to vasodilatation and increased 
endothelial damage, liquid leakes into the surrounding tissue and into the 
peritoneum with an accumulation of complement factors, immuneglobulines, 
and serum proteins. This phenomenon is clinically manifested as tissue edema 
(tumor) or ascites. The lymphoid vessels and the lymph nodes cause drainage 
of this fluid and initiation of the adaptive immune system. Endothelial damage in 
the site of infection causes exposition of the tissue thromboplastin to the 
coagulation system. The coagulation cascade, boostered by TNF and platelet 
activated factor (PAF) derived from macrophages and neutrophils, is activated 
on site. Thrombin is produced and blocks small blood vessels by fibrin formation 
thus, preventing further spreading of pathogens. 
Neutrophils and macrophages recognize microorganisms by PRR or by 
complement factor C3b marking and destroy them in their phagolysosomes. By 
production of reactive oxygen radicals and hydrogen peroxide (“oxidative burst”, 
stimulated by IL-8 and TNF), DNases, lipases, proteases and defensines they 
eliminate pathogens. Upon phagocytosis, these cells secrete more and more 
cytokines and chemokines that recruit more immune cells to the site of infection. 
The adhesion molecules selectins are expressed on the surface in response to 
LTB4, complement factor C5a or histamine released from mast cells upon 
contact with the vessel wall. Selectins bind to ligands on leukocytes, the Sialyl-
Lewis-Unit of glycoproteins, and reversibly stick to the endothelium. Due to the 
low blood flow leukocytes can roll on the vessel endothelium (leukocyte rolling). 
MIP-1a and TNF further povoke expression of the adhesion molecule 
intercellular adhesion molecule-1 (ICAM-1). On all leukocytes, the -integrin 
LFA-1 (CD11a:CD18) is expressed and recognizes ICAM-1 and ICAM-2. The -
integrin Mac-1 (CD11b:CD18, CR3) is expressed by macrophages, PMN and 
lymphocytes and recognizes membrane bound C3bi and fibrinogen. CR4 
(CD11c:CD18) found on macrophages and monocytes binds membrane bound 
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IL-8 (mouse functional analoga: MIP-2 and KC), promotes rearrangement of 
LFA-1 and Mac-1 on the leukocyte to form a high affine product for ICAM-1. 
Leukocytes are bound stronger to the vessel wall and begin to migrate through 
the vessel wall (extravasation, leukocyte diapedesis). This is mainly provoked 
by LFA-1/ICAM-1 interaction and by platelet endothelial cell adhesion   
molecule-1 (PECAM-1, CD31) that is expressed by leukocytes as well as in-
between endothelial cells. In tissue, leukocytes follow the concentration gradient 
of chemokines (i.e. IL-8, MCP-1, RANTES) to the site of infection (9). How 
diverse mechanisms of the innate immunity regulate defense against LPS and 
other microbial products to promote sepsis and multiple organ dysfunction is 
summarized in Figure 1. 
 
 
 
Figure 1: Pathogenic networks during sepsis. LPS and other microbial products simultaneously 
activate multiple parallel cascades that contribute to the pathophysiology of sepsis and septic 
shock. Reduced vascular stability and microvascular occlusion lead to coagulation, fever, 
vasodilatation, and capillary leakage provoking hypoperfusion and inadequate oxygenation and 
thus organ failure (16). 
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Adaptive Immunity 
In some cases the innate immune system alone is not able to eliminate all 
pathogens. However, it is still important to delay spreading of the infection until 
the adaptive immune response is activated. As antigen-presenting cells (APC) 
dendritic cells and macrophages present peptide fragments of phagocyted 
microorganisms to CD4
+ cells by their major histocompatibility complex II   
(MHCII). Thereby, the antigenspecific immune defense is activated. The T-cell 
receptor (TCR) of CD4
+ cells recognizes the specific peptid antigen by its 
variable region. The TCR-associated CD3-complex activates CD4
+ cells to 
induce a specific gene expression profile. Of special interest hereby is the 
induced secretion of IL-2. IL-2 in turn triggers autocrine activation of CD4
+ cells. 
This effect is further promoted by expression of surface molecules of the B7-
family on APCs, which bind to CD28 of lymphocytes, leading to an increased  
IL-2 mRNA stability and higher expression levels of the IL-2 receptors. IL-2 
induces proliferation of CD4
+ cells that now expand clonally. CD4
+ cells 
differentiate to effector cells that lack L-selectin so that they cannot be hold 
back in lymph nodes. Now, they express Very Late Antigen-4 (VLA-4) and bind 
to vascular cell adhesion molecule-1 (VCAM-1) on the endothelial wall and 
migrate to the site of infection. By interferon  (IFN) and IL-12, CD4
+ cells 
develop to inflammatory Th1-effector cells that in turn activate macrophages. By 
IL-4 and IL-6 in contrast they develop to become Th2-helper cells. The latter 
induce differentiation of B-lymphocytes to plasma cells and modulate the Th1-
response. Plasma cells in turn produce antigenspecific antibodies. As early as 
the first interaction of pathogen with cytokine-producing macrophages, the fate 
of the adaptive immune system to become cellular (Th1) or humoral (Th2) is 
defined. This in turn is important for the course of infection and the ability to 
eliminate pathogens. However, most protein antigens that are presented by 
MHCII complexes induce a mixed Th1 and Th2 cellular response. The 
differentiation of CD4
+ cells to a Th1 or Th2 phenotype is not only defined by 
secretion of different cytokines (Th1: mainly TNF and IFN versus Th2: mainly 
IL-4, IL-5, IL-10, and transforming growth factor  (TGF), but also by different 
surface markers. Th1 cells are characterized by CXCR3 and CCR5. Th2 cells INTRODUCTION     13 
express CCR4, CCR8 and less CCR3. This results in different chemotactic 
behaviour (9). 
 
To effectively combat invaded microorganisms and execute them, activated 
macrophages are necessary. Macrophage activation is the main duty of Th1-
cells. This activation is promoted by the cytokine IFN or by direct cell-cell 
contact. Th2 cells are not capable of activating macrophages; they secrete the 
macrophages inhibiting cytokine IL-20. On the one hand, macrophages are 
necessary to eliminate pathogens, however they might as well be harmful for 
the surrounding tissue by their ability to produce products of the “oxidative 
burst”. Therefore, activated macrophages need to be deactivated to decrease 
overwhelming self-harmful reactions. For this issue, three mechanisms are 
known so far: Cytokine production stops as soon as cell-cell contact of T-cell 
and macrophage is interrupted. Further, IFN-mRNA posses a relatively short 
half-life and is rapidly degradaded by a simultaneously expressed RNase. Third, 
Th2 cells secrete macrophage-inhibiting cytokines, such as TGF, IL-4, IL-10 
and IL-13. By TGF (direct) or by IL-10 (indirect) Th2 cells also decelerate 
activation and proliferation of Th1 cells. The presence of Th2 cells is therefore 
important for controlling and limiting effector mechanisms of activated 
macrophages (9). However, this mechanism might as well be deleterious when 
effector mechanisms of macrophages are highly needed to defend against 
pathogens. 
A scheme of the pathophysiological mechanisms of the innate and adaptive 
immune system during sepsis as a state of systemic inflammation is presented 
in Figure 2. 
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Figure 2: Sepsis pathophysiology. When bacteria enter the systemic circulation, they are 
detected and phagocytosed by innate immune cells, such as dendritic cells or macrophages. 
They in turn activate adaptive immune cells, such as B- and T-cells and promote complement 
activation. Immune cells secrete cytokines and chemokines, which provoke invasion of 
additional immune cells. Endothelial cells and granulocytes induce nitric oxide (NO) and 
reactive oxygen species (ROS) production, provoking dilatation of vessels, as well as 
endothelial damage and vascular leakage. Cell damage provokes the release of anti-
inflammatory mediators and T-cell apoptosis to limit self-harmful effects. Apoptotic T-cells in 
turn switch macrophages to an anti-inflammatory phenotype thus, inhibiting further ROS 
formation and bacterial clearance. In addition, the endothelial cells secrete tissue factor that 
promotes thrombin formation to increase fibrinogen and impair fibrinolysis. Blood flow is 
reduced, blood viscosity increased, vessels further occlude and the infection gets dominant 
again or even a secondary infection might arise. 
 
The coagulation cascade 
Cytokines are also important in inducing a procoagulant effect in sepsis. LPS 
and other microbial components initiate coagulation pathways leading to 
induced expression of tissue factor (TF) on PMN and endothelial cells. TF 
activates a series of poteolytic cascades, which result in the conversion of 
prothrombin to thrombin, which in turn generates fibrin from fibrinogen. 
Simultaneously, normal regulatory fibrinolytic mechanisms (fibrin breakdown by 
plasmin) are impaired because of high plasma levels of plasminogen-activator 
inhibitor type-1 (PAI-1) that prevents the generation of plasmin from the INTRODUCTION     15 
precursor plasminogen. The result is enhanced production and reduced 
removal of fibrin leading to the deposition of fibrin clots in small blood vessels, 
inadequate tissue perfusion and organ failure. Pro-inflammatory cytokines, 
especially IL-1 and IL-6, are important inducers of coagulation (17). Conversely, 
IL-10 regulates coagulation by inhibiting tissue factor expression on monocytes 
(16). 
An additional cause of the procoagulant state in sepsis is the downregulation of 
three naturally occurring anticoagulant proteins: antithrombin (AT), protein C 
(PC) and tissue factor pathway inhibitor (TFPI). These anticoagulants are of 
interest because in addition to their inhibitory effect on thrombin generation, 
they also have anti-inflammatory properties, including effects on release of 
monocyte-derived TNF by inhibiting activation of the transcription factors 
NFB and activator protein (AP)-1 (17). 
Attention has focused on PC, which is converted to the activated form (aPC) 
when thrombin complexes with thrombomodulin, an endothelial transmembrane 
glycoprotein. Once aPC is formed it dissociates from an endothelial protein C 
receptor (EPCR) before binding protein S, resulting in inactivation of factors Va 
and VIIIa and thus blocking the coagulation cascade. In sepsis aPC levels are 
reduced and expression of endothelial thrombomodulin and EPCR are 
impaired, providing evidence for successful therapeutic value of aPC 
replacement therapy (16, 18) (Figure 3). INTRODUCTION     16 
 
 
Figure 3:  Regulation of coagulation during sepsis. Normal homeostatic balance between 
procoagulant and anticoagulant mechanisms are disturbed during sepsis. Expression of tissue 
factor and plasminogen-activator inhibitor 1 (PAI-1) are enhanced, leading to increased 
production of prothrombin that is converted to thrombin which in turn generates fibrin from 
fibrinogen. PAI-1 impairs production of plasmin thus, fibrinolytic mechanisms by which fibrin is 
degradaded to FDP fail. Low levels of protein C and activated protein C (aPC) cause 
inactivation of factors Va and VIIa and inhibit PAI-1 which results in further procoagulant effects. 
Resulting fibrin clots in the microvasculature impair tissue oxygenation and promote cell 
damage (16). 
 
Compensatory anti-inflammatory response syndrome (CARS) 
Pathogens that invade the circulation cause an excessive production of 
inflammatory mediators. They in turn trigger systemic inflammation, provoking a 
vicious circle by increasing tissue damage and vascular leakage (19). To 
counteract the deleterious effects of the pro-inflammatory response, anti-
inflammatory mediators, such as soluble tumor necrosis factor receptor (sTNF-
R), IL-10, IL-1 receptor antagonist (IL-1ra) and TGF (20) are released. 
Described as most deleterious during CARS is the immune cell apoptosis that is 
unevenly observed in sepsis and mostly affects lymphocytes in blood and 
spleen. Apoptosis can cause immunosuppression by two mechanisms: INTRODUCTION     17 
depletion of various immune cells resulting in the loss of key anti-microbial 
function and inducing immunosuppressive effects in surviving cells. As a 
consequence of T-cell apoptosis an immunoparalysis occurs, which renders the 
septic host susceptible to secondary or opportunistic infections (21) and 
correlates with sepsis mortality (19, 22-23). This concept of compensatory anti-
inflammatory response syndrome (CARS) was proposed by Roger Bone in 
1997 to describe the consequences of the counter-regulatory mechanisms 
initiated to limit the overwhelming inflammatory process in patients with 
infectious (sepsis) or non-infectious (SIRS) diseases. One major consequence 
of CARS is the modification of the immune status that could favor the enhanced 
susceptibility of intensive care patients to nosocomial infections (20). Some 
studies indicate a correlation between the severity of the immunosuppression 
and an increased probability of developing severe sepsis. In line, several “two 
hit” animal models suggested that following a first insult, an enhanced 
susceptibility to infection occurs. For example, a first infection, usually a 
peritonitis, which is experimentally induced either by i.p. injection of E.coli or by 
CLP, renders the animals more susceptible to a secondary bacterial or fungal 
lung infection (24). In fact, most of the patients with sepsis or septic shock 
undergoing an immunosuppression do not die from the initial systemic infection, 
but from a second or third hit, that they acquire during their ICU stay (25). 
Furthermore, it is hypothesized that the increased risk of death or 
rehospitilization following sepsis survival correlates with a prolonged state of 
immunosuppression and persistent infections (25). 
Among other studies, Hotchkiss et al. (26-27) have clearly demonstrated that 
extensive T-cell apoptosis in animal models of sepsis and in septic patients is 
an important pathogenic event. Results from animal models exhibit improved 
sepsis survival rates due to abrogation of T-cell apoptosis (28). However, CARS 
is not a general phenomenon that dampens all immune function, it is rather an 
adaption depending on the compartments (i.e. blood or tissue), the type of 
primary or secondary infection, the nature of the studied function, the nature of 
the produced mediators, and the nature of the leukocytes. For example, 
apoptosis can either be enhanced in e.g. lymphocytes and dendritic cells, 
remain unchanged in e.g. monocytes, or be decreased in neutrophils (29-30). INTRODUCTION     18 
Recent clinical studies primarily targeted the initial pro-inflammatory immune 
response, since correlations between production of pro-inflammatory mediators 
and severity and mortality of the disease exist (31). However, clinical trials 
attenuating the inflammatory response, using high-dose corticosteroids, tumor 
necrosis factor antagonists, anti-endotoxin antibodies and interleukin-1-receptor 
antagonists were so far disappointing, potentially through suppression of the 
host’s ability to fight primary or secondary infections (25, 29, 32-33). Thus, 
preventing lymphopenia by inhibition of T-cell apoptosis can be envisioned as 
an option to improve long-term morbidity after sepsis by advancing the host’s 
ability to fight against secondary infections. 
In the beginning of sepsis, the pro-inflammatory answer (SIRS mediators) and 
the anti-inflammatory response (CARS mediators) are balanced, once SIRS 
mediators or once CARS mediators are more abundant. However, during septic 
shock, this balance is disrupted and exaggerated thus, provoking the severe 
symptoms of sepsis such as organ dysfunction, septic shock and eventually 
death (Figure 4). 
 
 
 
Figure 4: SIRS and CARS during inflammation. The inflammatory response can be envisioned 
as a balanced response of pro-inflammatory mediators (during SIRS) and anti-inflammatory 
mediators (during CARS). SIRS mediators are IL-1, IL-6, IL-12, TNF, and diverse chemokines. 
They in turn activate CARS mediators, such as IL-1 receptors antagonist (IL-1ra), TGF, IL-4, 
IL-10, and IL-13. During septic shock, the balanced regulation of SIRS and CARS mediators is 
dysregulated and exaggerated and it comes to a dysfunctional inflammatory response (34). INTRODUCTION     19 
3.2. PPAR 
3.2.1.  Between transcription and transrepression 
The peroxisome is a subcellular organ with several important functions including 
the removal of molecular oxygen and subsequent breakdown of hydrogen 
peroxide, glycerolipid synthesis, cholesterol biosynthesis and decomposition, as 
well as fatty acid oxidation. An orphan nuclear receptor that is activated by 
peroxisome proliferators provided further insights into the molecular 
mechanisms by which peroxisomes promote their pleiotropic effects. This 
receptor, namely peroxisome proliferator-activated receptor (PPAR), belongs to 
the nuclear hormone receptor superfamily that further includes estrogen 
receptors, thyroid hormone receptors, retinoic acid and vitamin D3 receptors as 
well as retinoid X receptors (RXRs) (35). Since the discovery of the first PPAR 
by Issemann and Green in 1990 (36), the role of this class of nuclear receptors 
in normal physiology and pathophysiology has become more and more 
relevant. Similar to other members of the nuclear receptor superfamily, PPARs 
possess a central DNA-binding domain that recognizes PPAR response 
elements (PPREs) in the promoter region of their target genes. The 
transcriptional regulation of target genes by PPARs is achieved by 
heterodimerization of PPARs with RXR and binding to PPREs. RXR also forms 
heterodimers with other members of the nuclear receptor superfamily, 
provoking competition between the heterodimerization partners and interaction 
with PPAR-dependent transcription. PPAR-RXR heterodimers can also bind to 
a PPRE in the absence of a ligand. Although the presence of ligand-bound 
PPAR-RXR at the PPRE is typically associated with transcriptional activation, 
the presence of unliganded PPAR-RXR at a PPRE has effects that vary 
depending on the promoter context and cell type. There are three isoforms 
described: PPAR, PPAR, and PPAR. PPAR was the first identified isoform 
and responds to several compounds inducing peroxisome proliferation, where 
this subfamily was named after. The other PPARs do not share this 
functionality. 
PPAR is expressed most abundant in adipose tissue and is a master regulator 
of adipogenesis. PPAR activation promotes adipocyte differentiation and is INTRODUCTION     20 
associated with induction of lipogenic enzymes and glucoregulatory molecules 
(37). However, PPAR is also found in other cell types, including fibroblasts, 
hepatocytes, myocytes, colon and breast epithelial cells, the white and red pulp 
of the spleen, activated T-cells, human bone marrow precursors, and 
macrophages/monocytes (38). For some PPAR target genes in adipocytes, 
unliganded PPAR-RXR heterodimers recruit corepressor complexes, resulting 
in active repression, whereas other gene corepressors are not recruited by 
unliganded PPAR-RXR (39). 
3.2.2. Structure 
Structure of the PPAR protein 
Three isoforms of the PPAR family were identified so far, encoded by separate 
genes: PPAR, PPAR, and PPAR. These three isotypes display dissimilar 
patterns of tissue distribution and differ in their ligand-binding domains (36). 
PPAR expression is controled by different promoters, leading to the PPAR1 
isoform (475 amino acids) and PPAR2 isoform (additional 30 amino acids at 
the N-terminus) that differ mainly in their expression patterns. PPAR1 isoform 
expression is found in nearly all tissues except muscle, and the PPAR2 isoform 
is primarily expressed in adipose tissue and the intestine. Alternative 
transcription is accomplished by the use of three established promoters, 
whereas transcript variant 1 and 3 code for protein PPAR1 and transcript 
variant 2 codes for PPAR2 (40). Besides these three, another 5 transcript 
variants have been identified in the last decade (41-42), but it remains elusive 
whether they have further and distinct function. 
The structure of the PPAR1 protein was fist discovered by Nolte et al. using X-
ray-Raman scattering. Likewise other nuclear receptors, PPAR consists of five 
domains (Figure 5). The N-terminus contains the ligand-independent activation 
domain (A/B), also known as AF1 (activation function 1). The DNA-binding 
domain (DBD) consists of two zinc-finger-motifs, which allow the protein to 
interact with the PPRE on the DNA. Next, the hinge domain (HD) assigns 
flexibility in concers of ligand and DNA binding. Thus, the protein is able to 
interact directly with other proteins. By this ability, PPAR promotes effects that INTRODUCTION     21 
are independent of its transcriptional potential, and modifies different signaling 
pathways. At the C-terminus of the PPAR protein the ligand binding domain 
(LBD) is localized, as well as the ligand-dependent activation domain AF2 
(activation function 2) (43). 
 
 
 
Figure 5: PPAR domain structure. The structure of PPAR shows the characteristic nuclear 
receptor configuration of five domains (A/B, C, D, E, F). The DNA-binding domain (DBD; 
domain C) and the ligand-binding domain (LBD, domain E) are highly conserved. The amino-
terminal A/B domain represents the ligand-independent activation domain 1 (‘activation function 
1’, AF1). At the C-terminal site, the ligand-dependent domain (‘activation function 2’, AF2, 
domain F) and the LBD are localized. The domain D consists of a variable Hinge-domain and 
plays an important role for conformational changes. 
 
Structure of synthetic ligands and their mode of action 
The most prominent synthetic PPAR ligands are the thiazolidinediones (TZDs). 
All TZDs feature a similar 2,4-thiazolidinedione-structure motif. This structure 
can be basically divided into three parts: an acidic head-group (blue), a central 
aryl-spacer (red) and a lipophilic end part (yellow). This structure reminds, at 
least in part, of a fatty acid derivate, similar to the previously reported natural 
ligands (Figure 6). 
 
 
 
Figure 6: Chemical structure of rosiglitazone and the synthetic antagonist GW9662. The general 
structure of a TZD displays a thiazolidinedione head group (blue), a central aryl-spacer (red) 
that is attached by a linker (green) to a lipophilic end part (yellow). 
 INTRODUCTION     22 
The structure of the TZDs was chemically modified to improve selectivity and 
affinity. It was shown that introducing a heterocyclic N-atom in the lipophilic part 
(yellow), as seen in rosiglitazone (Figure 6), significantly improves the affinity to 
the receptor. This is due to formation of a covalent hydrogen bond of the N-
atom to Cys
285 in the LBD of PPAR (44). GW9662 is a specific inhibitor of 
PPAR with only minor effects on the other PPARs (IC50 PPAR: 3.3 nM; IC50 
PPAR: 30 nM; IC50 PPAR: 2000 nM) (45). GW9662 mediates its inhibitory 
potential by effects on receptor organization. Leesnitzer et al. (2002) explored 
the mode of binding of GW9662 by biochemical experiments using samples 
with GW9662-modified PPAR and mass spectometry. They found GW9662 to 
covalently bind to Cys
285 in the LBD (45). However, in 2006 Hamuro et al. 
described this finding as “not well understood” and reported that unlike full 
agonists (TZDs), no conformational or dynamic change occurs in this region 
upon the antagonist GW9662 binding to PPAR. It remains as dynamic as the 
ligand-free form, proposing no covalent binding of GW9662 in the LBD to Cys
285 
(46). In line, in 2008 Chandra et al. underlined this result by reporting that 
GW9662, compared to rosiglitazone, does not bind to Cys
285, but resides in the 
pocket without having made the covalent bond in the intact PPAR (Figure 7). 
 
 
 
Figure 7: Effect of different ligands on the PPAR-RXR complex. Comparison of the binding 
mode of rosiglitazone with that of GW9662 within the PPAR-LBD pocket. GW9662 does not 
form a covalent bond with Cys
285 in the ligand binding pocket of PPAR (adapted from Chandra 
et al. 2008). 
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Nevertheless, the positioning of the nitro-aryl chloride portion of GW9662 shows 
this ligand is ready to form a covalent adduct, given the proximity of its 
displaceable chloride group to the cysteine sulphur (47). Another possible 
binding site for GW9662 within the LBD of PPAR was not proposed in the 
literature so far. In general, it is hypothesized that binding of agonists within the 
ligand-binding site causes a conformational change where coactivator binding is 
stabilized. In contrast, binding of antagonists results in a conformation that 
favors binding of corepressors. 
3.2.3. PPAR ligands 
PPAR ligands include a surprisingly diverse set of natural ligands (37). In the 
context of sepsis the PPAR agonist needed for the induction of cell death may 
be provided by endothelial cells or macrophages under inflammatory or septic 
conditions, most likely as a by-product of cyclooxygenase-2 activity (48). 
Enhanced levels of the physiological PPAR agonist 15-deoxy-∆
12,14-
prostaglandin J2  (15d-PGJ2) have been detected in blood samples of septic 
patients (49). Other factors that are likely to be generated during sepsis with a 
high affinity to PPAR are lipoxygenase products such as 15-
hydroxyeicosatetraenoic acid (15-HETE), 9-hydroxyoctadecadienoic acid (9-
HODE), and 13-hydroxyoctadecadienoic acid (13-HODE). Especially the 
identification of fatty acid derivates as selective PPAR ligands that are 
generated during inflammatory processes, proved special importance for 
PPAR in regulating immunological processes. Furthermore, it has been 
described that LPS increases the susceptibility of low-density lipoprotein (LDL) 
towards oxidation, generating oxidized-LDL as a specific PPAR agonist (50). 
The isolation and identification of these endogenous ligands during sepsis has 
yet to be performed. Moreover, we cannot exclude that multiple factors are 
responsible for PPAR activation during sepsis. In fact, the volume of the 
ligand-binding cavity of PPAR is much larger than pockets of other nuclear 
hormone receptors (PPAR: 1619 Å versus vitamin D receptor: 871 Å, retinoid X 
receptor  α: 687 Å, progesterone receptor: 557 Å and estrogen receptor:   
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range of endogenous ligands (51) that are likely to be produced during sepsis. 
Further findings raise the possibility that PPAR can bind two ligand molecules 
at once. This could explain why its ligand binding pocket is unusually large 
compared to that of other nuclear receptors. The proposed simultaneous ligand 
binding would also underline the hypothesis that PPAR is not a specific target 
for one particular ligand, but it is a sensor molecule that scans the intracellular 
mixture of various fatty acid molecules (52). 
Synthetic ligands are the insulin sensitizing thiazolidinediones (TZDs, such as 
englitazone, ciglitazone, pioglitazone, rosiglitazone, troglitazone), non-steroidal 
anti-inflammatory drugs (NSAIDs, i.e. indomethacin, fenoprofen, flufenarnic 
acid), tyrosine derivates (farglitazar, GW7845), and a variety of new chemical 
classes (37, 39). In humans, TZDs enhance insulin action, improve glycemic 
control with a significant reduction in the level of glycated haemoglobin (HbA1C), 
and have variable effects on serum triglyceride levels in patients with type 2 
diabetes. Despite their proven efficacy and widespread use, these drugs 
possess a number of deleterious side effects, including significant weight gain 
and peripheral edema (37). These side effects emphasize the critical need for 
the discovery and characterization of alternative PPAR modulators that would 
retain the antidiabetic properties while avoiding the side effects. PPAR 
modulators so-called SPPARMs (selective PPAR modulators) have been 
designed displaying different binding properties to the PPARs compared to full 
agonists (51, 53). The “dual”, “balanced” or “pan” PPAR ligands are a group of 
drugs, which bind two or more PPAR isoforms. These drugs are currently under 
investigation for treatment of a larger subset of symptoms of the metabolic 
syndrome. These include the experimental compounds aleglitazar, muraglitazar 
and tesaglitazar (51). Known synthetic PPAR antagonists are i.e. biphenol A 
diglyceridyl ether (BADGE), GW9662, SR-202, CDDO-Me, PD068235, 
Diclofenac, and T0070907 (48). 
3.2.4. Anti-inflammatory  properties 
PPAR acts as a transcriptional activator of many adipocyte-specific genes 
involved in lipid synthesis, handling and storage of lipids, growth regulation, 
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activity, recent observation showed that PPAR can directly bind to other 
proteins and inhibits signal transduction (Figure 8). This ability is called 
transrepression and assigns PPAR the capability to inhibit pro-inflammatory 
signaling and induce an anti-inflammatory response (55-56). Transrepression is 
mainly mediated by direct protein-protein interactions between PPAR and 
other transcription factors, such as NFB (57-59), NFAT (60), AP-1 (59, 61), or 
STAT (62). In contrast to direct sequence-specific interaction of PPAR with 
DNA itself this mechanism scavenges transcription factors from binding to their 
responsive elements. PPAR inhibits pro-inflammatory signaling and induces an 
anti-inflammatory response. Of special importance is this ability in immune cells, 
where PPAR activation reduces expression of pro-inflammatory cytokines, 
such as IL-2, TNF, IL-1, and IL-12. Further PPAR-dependent 
transrepression is mediated by PPAR binding to co-activator complexes, which 
are essential for transcription factor-dependent transactivation, such as steroid 
receptor co-activator 1 (SRC1) and cAMP response element binding protein 
(CREB)-binding protein (CBP)/p300. These complexes confer histone 
acetyltransferase activity and reorganize the chromatin packaging, to allow the 
transcriptional machinery gaining access to the promoter region (63). Thus, 
NFB and AP1-mediated gene induction (64-65) and pro-inflammatory cytokine 
expression is inhibited. In its SUMOylated form, PPAR transrepresses gene 
expression by preventing removal of the co-repressor complex nuclear receptor 
co-repressor/silencing mediator for retinoid and thyroid hormone receptors 
(NCoR/SMRT) from the promoter region of pro-inflammatory transcription 
factors (NFB), which, through association with histone deacetylases (HDACs), 
attenuates gene transcription (66-67). Besides transrepression PPAR inhibits 
mitogen-activated protein kinase (MAPK) by a so far unknown mechanism (68-
70). This prevents MAPK from phosphorylating and thereby activating 
downstream pro-inflammatory transcription factors. In addition, cytosolic PPAR 
directly binds protein kinase C  (PKC). Subsequently its translocation to the 
cell membrane is inhibited, leading to attenuated activation and further 
depletion. In monocytes/macrophages this provokes desensitization in response 
to apoptotic cell phagocytosis, where attenuated PKC signaling blocks 
NADPH-oxidase-dependent ROS formation (71). INTRODUCTION     26 
 
 
 
Figure 8: PPAR-dependent repression of pro-inflammatory cytokine production. Ligand-
activated PPAR dimerizes with the retinoid X receptor (RXR) . In this state, (A) PPAR can 
directly associate with pro-inflammatroy transcription factors, such as STAT, NFAT, AP-1, or 
NFB thus, preventing pro-inflammatory gene expression. Further, (B) PPAR scavenges co-
activators from binding to pro-inflammatory transciption factors (TF) or (C) inhibits degradation 
of co-repressors. E.g. it was shown that SUMOylated PPAR reduces degradation of   
NCo-R/HDAC3/TLB1/TLBR1 complex and prevents NFB-dependent gene expression. Besides 
these mechanisms of transrepression PPAR directly inhibits MAPK and downstream signaling. 
By inhibiting PKC translocation, PPAR attenuates NADPH oxidase activation. 
Heterodimerization with RXR is not required in the latter two cases (38). 
3.3. Apoptosis 
3.3.1.  Apoptosis versus necrosis 
Througout the entire life of an organism, besides cell proliferation also a 
controlled cell death takes place. We differentiate between two major forms of 
cell death: apoptosis and necrosis. Necrosis occurs in cells that were severely 
damaged. Necrotic cells release toxic substances into the surrounding, which 
promotes inflammatory reactions. Markers for necrosis are: swelling, loss of 
membrane integrity, release of cell contents, loss of cell organells, and 
decomposition of DNA by endonucleases and exonuclases. The inducible form INTRODUCTION     27 
of cell death, apoptosis, also known as programmed cell death or non-necrotic 
cellular suicide, is described in the following (72-73). 
3.3.2.  Regulation of apoptosis 
The extrinsic way (death receptor pathway) 
Apoptosis can be initiated by different stimuli that all end up in activation of 
caspases (“cystein-specific aspartate proteases”). On the one hand, apoptosis 
is mediated by binding of extracellular ligands on transmembrane receptors. 
Under physiologic conditions this is mostly mediated by stimulation of death 
receptors such as TNF-receptor 1 (TNF-R1), Fas-receptor (Fas-R), death 
receptor 4 or 5 (DR4/DR5), TNF-related apoptosis-induction ligand receptor 1 
(TRAILR1) and TRAILR2. Ligand binding provokes formation of a mulitmeric 
complex, the death inducing signaling complex (DISC) that contains the death-
receptor (e.g. Fas-R), adaptor molecules, such as Fas-associated death 
domain-containing protein (FADD) and caspase 8. Caspases are a class of 
cysteine proteases that includes several representatives involved in apoptosis. 
They convey the apoptotic signal in a proteolytic cascade cleaving and 
activating other caspases that then degrade other cellular targets provoking cell 
death. Caspase 8 is the initial caspase involved in response to receptors with a 
death domain like Fas. Active caspase 8 results from proteolytic splicing and in 
turn activates effector-caspases, such as caspase 3. Substrates of the caspase 
cascade are i.e. structural proteins such as -actin and nuclear laminine, DNA 
repairing enzymes such as poly-ADP-ribose polymerase 1 (PARP1), as well as 
anti-apoptotic Bcl-2 familiy members. Another typical substrate for caspases is 
the inhibitor of caspase-activated DNase (ICAD). ICAD splices chromosomal 
DNA during apoptosis in between nucleosomes, which results in fragmented 
DNA (72-73). 
 
The intrinsic pathway (mitochondrial-mediated pathway) 
Caspases can as well be activated by cell intrinsic signals, such as damage of 
DNA and activation of p53. Other factors inducing intrinsic apoptosis are loss of 
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are mitochondria. This mitochondrial stress pathway is initiated by the release 
of cytochrome c, a protein of the respiratory chain, from mitochondria 
membranes. In the cytoplasma, cytochrome c interacts with the adapter 
molecules apoptosis protease activating factor-1 (Apaf-1), causing self-
cleavage and, in cooperation with desoxy-ATP, activation of caspase 9. This 
complex is called apoptosome. At this stage apoptosis can be inhibited by 
interaction of the apoptosome with heat-shock proteins (HSP). In presence of 
ATP, downstream caspases 3, 6, and 7 are activated by the upstream 
proteases and act themselves to cleave cellular targets, fragmentate DNA and 
induce cell death. Caspases can be inhibited by inhibitors of apoptosis proteins 
(IAPs). As described above, cytochrome c is released from the mitochondrial 
membrane through pores to the cytosol. These pores are built by pro-apoptotic 
members of the Bcl-2-family. Members of the Bcl-2 family belong to three 
subclasses: one anti-apoptotic class, and two pro-apoptotic classes. The two 
pro-apoptotic classes are the multiple-domain-proteins (Bax and Bak) and 
proteins that have only one single regulatory domain (BH3-only proteins, such 
as Bid, Bad, Noxa, Puma, Bim) (Table 3). Upon injury, the pro-apoptotic 
members, such as Bad and Bax, translocate to mitochondria where they bind 
Bcl-2 and Bcl-xl, neutralize their anti-apoptotic properties by building pores in 
the mitochondrial membrane thus, inducing changes in mitochondrial 
membrane potential (MMP) (74). The structure of the Bcl-2 proteins shows a 
striking similarity to the overall fold of the pore-forming domains of bacterial 
toxins (75). Anti-apoptotic members are important to ensure membrane integrity 
and inhibit cytochrome c release by binding Bax and Bad, which are responsible 
for cytochrome c release. The membrane potential is therefore maintained by a 
balance between anti-apoptotic Bcl-2 family proteins, notably Bcl-2 and Bcl-xl, 
and pro-apoptotic familiy members such as Bad, Bim and Bax (72-73). A series 
of stimuli regulate the amount and activity of every Bcl-2 protein family member. 
Main regulatory proteins are the tumor-suppressor protein p53 as well as Bax, 
Puma, Noxa and proteins of the PI3K/Akt pathway (73) (Table 3). 
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Table 3: Regulation of pro- and anti-apoptotic members of the Bcl-2 protein family (73). 
Protein Regulation 
Proapoptotic (Multiple domain proteins) 
Bax, Bak  Transcription induced by p53 
Proapoptotic (BH3-only-protein) 
Bid  Activated upon enzymatic splicing of caspase 8 
Bad  Inactivated by phosphorylation by Akt-kinase 
Noxa, Puma  Transcription induced by p53 
Bim  Transcription inhibited by Akt-kinase 
Antiapoptotic 
Bcl-2 Transcription 
 
Apoptosis during sepsis 
Defining death pathways during sepsis is important because insight provided 
into the mechanisms of cell death might present potential therapies. For 
example, involvement of the death receptor pathway points to members of the 
TNF receptor family, and several specific receptor antagonists are capable of 
blocking these sites. Involvement of the mitochondrial-mediated pathway 
suggests stress-induced mitochondrial injury, which occurs during oxidative 
stress. Antioxidant therapy proved to be promising in some models of 
apoptosis. Hotchkiss et al. found in 2005 an increase in activation of caspases 8 
and 9, which indicates that lymphocyte apoptosis may be occurring by both 
extrinsic and intrinsic pathways. Further, they determined active caspase 3-
positive, Bcl-2-negative lympohocytes as well as active caspase 3-positive, Bcl-
2-positive lymphocytes, which suggests mitochondrial-mediated apoptosis and 
death receptor-mediated apoptosis (76). Studies in animal models of sepsis 
support the concept that lymphocyte apoptosis in sepsis is a results of both 
pathways. Ayala et al. showed that sepsis-induced lymphocyte apoptosis can 
be attenuated and survival of mice can be improved by administration of 
compounds that block the Fas death receptor (77). However, studies from three 
other independent laboratories have shown that lymphocytes from Bcl-2 
overexpressing mice are resistant to sepsis-induced apoptosis and provoking 
improved survival (78-80). INTRODUCTION     30 
Of special importance during sepsis are the Bcl-2 protein family members Bcl-2 
and Bim. It was shown that overexpression of Bcl-2 prevented apoptosis and 
improved outcome in sepsis. These findings showed that lymphocytes from   
Bcl-2 transgenic mice were resistant to sepsis-induced apoptosis, and that 
these mice had a threefold improvement in survival compared to controls (80). 
Subsequently, several groups have shown that sepsis decreases the level of 
expression of Bcl-2 by lymphocytes which might be one mechanism responsible 
for, or that contributes to, the apoptosis of lymphocytes (76, 81-82). Bcl-2 
protects against apoptosis by binding to and neutralizing the pro-apoptotic 
family members, such as Bim, Puma, and Noxa (83). Bim is the most 
extensively studied one of these proteins and is required for cell death 
secondary to cytokine withdrawal, death of autoreactive T-cells, and for 
termination of acute T-cell responses to viral infections (84-86). Hotchkiss et al. 
showed that Bim knockout mice have nearly complete protection against 
sepsis-induced lymphocyte apoptosis and a distinct survival advantage in a 
cecum ligation and puncture model of septic peritonitis (87). In line, RNA 
interference (with small interfering RNA, siRNA) provided a way to transiently 
imitate a genetic knockout in a clinical setting. Further they proposed that this 
siRNA-induced decrease in Bim expression results in liberation of sufficient   
Bcl-2 to effectively bind to and inhibit Bax/Bak channel formation, thereby 
blocking apoptosis (88). In special regard to these important studies, this thesis 
focusses on regulation of Bcl-2 and Bim by PPAR. 
3.4. Preliminary  data:  PPAR during sepsis 
T-cells of septic patients showed an up-regulation of PPAR and their sera 
contained a PPAR agonist. The up-regulation was shown to sensitize T-cells of 
septic patients towards apoptosis. This implies that PPAR plays a significant 
role in T-cell apoptosis, contributing to lymphocyte loss in sepsis and an 
inhibition of PPAR may turn out to be beneficial for patients suffering from 
lymphopenia during sepsis (89). While there were indications that PPAR 
activation modulates T-cell fate, the importance of PPAR for T-cell apoptosis, 
sepsis outcome and the underlying mechanisms remained elusive. INTRODUCTION     31 
3.5.  Aims of this study 
The present thesis aimes at elucidating the role of PPAR during sepsis 
progression and especially focusses on its role in apoptosis induction, the 
underlying mechanisms and its potential as a new therapeutic target during 
sepsis. 
Based on previous results, I hypothesized that activation of PPAR during 
sepsis induces apoptosis of peripheral T-cells in spleen and in blood. 
Consequently, this T-cell depletion contributes to an immune paralysis and 
impairs the host susceptible to secondary infections, leading to high mortality 
rates. Therefore, in my experiments I first aimed at clarifying the question 
whether manipulating PPAR functionality by genetical ablation of the PPAR 
gene in mice prevents T-cells from apoptosis and increases survival. My next 
aim was to elucidate the underlying pathway for PPAR-dependent apoptosis. 
In this regard I specifically focused on regulatory proteins that have been 
described in the literature to be important during T-cell apoptosis. Special 
interest was given on the investigation of the therapeutic potential of PPAR. 
Therefore, experimental sepsis using a specific PPAR inhibitor that is supplied 
post-sepsis to prevent PPAR activation and eventually T-cell depletion should 
be performed. Additionally, I intended to clarify whether this treament regime 
results in higher survival rates in my experimental sepsis model. Further, I was 
intrigued to investigate the underlying pathway of apoptosis prevention in T-
cells in this setup of pharmacological PPAR inhibition. Finally, I intended to 
elucidate whether higher T-cell counts improved survival by executing effects on 
classical sepsis-related parameters, such as bacterial clearance and end organ 
damage. 
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4. MATERIAL AND METHODS 
4.1. Material 
4.1.1. Mice 
C57BL/6N-PPAR
fl/fl   kindly provided by Dr. Frank Gonzalez, 
NCI, Bethesda, USA 
C57BL/6NTac-(Tg)(lck-Cre)     Taconic, Germantown, USA 
 
C57BL/6N-PPAR
fl/fl and C57BL/6NTac-(Tg)(lck-Cre) were crossed to breed 
C57BL/6N-lck-Cre;PPAR
fl/fl containing a conditional depletion of the PPAR 
protein in T-cells. 
 
Mice were kept in a temperature-controlled room with 12 h light and 12 h dark 
diurnal cycle. They were housed in filter-topped cages and were fed standard 
laboratory chow and water ad libitum. All animal experiments followed the 
guidelines of the Hessian animal care and use committee (Table 4). 
 
Table 4: List of animal trial permissions 
Short title of animal trial permission  Authorization number 
„T-Zelldepletion“  F144/01 
„T-Zelldepletion bei ZLP“  F91/51 
„Hemmung der T-Zelldepletion bei Sepsis”  F144/06 
 
 
4.1.2.  Chemicals, Reagents and Kits 
Table 5: List of chemicals, reagents, kits and their providers 
Chemical/Reagent/Kit Provider 
Absolute™ qPCR SYBR® Green Mix  ABgene (Hamburg) 
Acid washed glass beads  Stratagene (Heidelberg) 
Agarose Sigma-Aldrich  (Steinheim) 
APO-BRDU TUNEL kit  Phoenix Flow Systems (San Diego) MATERIAL AND METHODS     33 
Bepanthen
® (Dexpanthenol)  Bayer (Leverkusen) 
Brefeldin A  Sigma Aldrich (Steinheim) 
BSA (bovine serum albumin) Roth  (Karlsruhe) 
Catalyzed Signal Amplification kit  Dako Inc. (Glostrup) 
Chelex
®100 BioRad  (Munich) 
Columbia Agar  Hypha Diagnostica (Heidelberg) 
CytokineBeadArray Mouse Inflammation kit  BD Bioscience (Heidelberg) 
DAB (diaminobenzidine tetrahydrochloride)  Dako Inc. (Glostrup) 
Deoxynucleotide Solution Mix (dNTPs)  New England Biolabs (Frankfurt) 
EDTA (ethylenediaminetetraacetic acid)  AppliChem (Darmstadt) 
Endo Agar  Hypha Diagnostica (Heidelberg) 
Eosin G  Merck (Darmstadt) 
Ethanol Sigma-Aldrich  (Steinheim) 
FCS (fetal calf serum)  PAA Laboratories (Cölbe) 
Formaldehyd Riedel-de-Haen  (Seelze) 
GeneRuler™ Fermentas  (St.  Leon-Rot) 
Glycine Merck  (Darmstadt) 
GW9662  Cayman Chemical (Ann Arbor) 
H2O2 (Hydrogenperoxide)  Merck (Darmstadt) 
iScript™ cDNA Synthesis Kit  BioRad (Munich) 
Ketavet
® (Ketamine)  Pfizer vet. (Zurich) 
Lipopolysaccharide (from E. coli, 0127:B8)   Sigma-Aldrich (Steinheim) 
Maxer’s hematoxyllin  Roth (Karlsruhe) 
NaCl (sodium chloride)  Sigma-Aldrich (Steinheim) 
Needles (18-27 gauge)  BD Bioscience (Heidelberg) 
NP-40 (nonyl phenoxylpolyethoxylethanol)  Sigma-Aldrich (Steinheim) 
Nuclear ORANGE  eBioscience (Frankfurt) 
Pan T-cell Isolation kit for AutoMACS  Miltenyi Biotec (Bergisch-Gladbach) 
Paraformaldehyd Merck  (Darmstadt) 
PCR Purification kit  Qiagen (Hilden) 
peqGOLD RNAPure™  PeqLab Biotechnologie (Erlangen) 
PPRE lentivector  System Biosciences (Mountain View) 
Prolene
® 5-0   Ethicon Inc (Norderstedt) 
Protease Inhibitor Cocktail Mix (PIM)  Roche (Basel) 
Protein G-Agarose Beads  Roche (Basel) 
Protein Ruler  Fermentas (St. Leon-Rot) 
Proteinase K  Invitrogen (Darmstadt) 
PureLink® PCR Purification Kit  Invitrogen (Darmstadt) 
Rompum
® (Xylazine)  Bayer vet. (Leverkusen) 
RPMI (Rosswell Park Memorial Institute)  PAA Laboratories (Cölbe) 
Salmon Testes DNA  Invitrogen (Darmstadt) MATERIAL AND METHODS     34 
SDS (sodium dodecyl sulfate) Roth  (Karlsruhe) 
Syringes (2-20 ml)  B.Braun (Melsungen) 
Taq DNA Recombinant PCR kit  Invitrogen (Darmstadt) 
Temgesic
® (Buprenorphine)  Essex Chemie AG (Clifton) 
Thioglycollate-G Hypha  Diagnostica  (Heidelberg) 
 
4.1.3. Antibodies 
Table 6: List of antibodies for Western and FACS analysis 
Antigen Source  Provider 
Actin  Rabbit  Sigma Aldrich (Steinheim) 
Akt  Mouse  Cell Signaling Technology (Danvers) 
Anti-rabbit-IgG Rabbit  Vector  laboratories Inc. (Burlingame) 
Bcl-2  Rabbit  BD Bioscience (Heidelberg) 
Bim  Mouse  Cell Signaling Technology (Danvers) 
Biotinylated-IgG  Rabbit  Vector Laboratories Inc. (Burlingame) 
CD3-APC  Mouse EuroBioScience  (Friesoythe) 
CD3-FITC  Mouse  EuroBioScience (Friesoythe) 
CD45-pacific blue  Mouse  BD Bioscience (Heidelberg) 
CD4-PE Mouse  EuroBioScience (Friesoythe) 
CD8a-APC Mouse  Miltenyi Biotec (Bergisch-Gladbach) 
Cleaved caspase 3  Rabbit  Cell Signaling Technology (Danvers) 
Fc-Block Mouse  BD Bioscience (Heidelberg) 
IgG Rabbit  Upstate  Biotechnology (Billercia) 
IL-2-PE Mouse  BD Bioscience (Heidelberg) 
LEAF
TM Purified IgG isotype control  Rat  BioLegend (Uithoorn) 
LEAF
TM Purified anti-mouse IL-2  Rat  BioLegend (Uithoorn) 
Mouse-IRDye680 Donkey  LI-COR  (Lincoln) 
Mouse-IRDye800CW Donkey  LI-COR  (Lincoln) 
NFAT  Rabbit  Santa Cruz (Santa Cruz) 
pAkt  Rabbit  Cell Signaling Technology (Danvers) 
PPAR  Rabbit  Santa Cruz (Santa Cruz) 
Rabbit-IRDye680 Donkey  LI-COR  (Lincoln) 
Rabbit-IRDye800CW Donkey  LI-COR  (Lincoln) 
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4.1.4. Oligonucleotides 
Oligonucleotides were purchased from Biomers.net GmbH (Ulm) and described 
in Table 7. For amplification of mouse IL-2, Actin, PPAR, and Bcl-2 QuantiTect 
Primer Assay from Qiagen GmbH (Hilden) were used. 
 
Table 7: List of oligonucleotides 
Name  upsteam primer  downstream primer 
Bim  5’-GGCCAAGCAACCTTCTGATG-3’  5’-GCCTTCTCCATACCAGACGG-3’ 
ChIP-IL-2  5’-TTTGTCCACCACAACAGGCT-3’ 5’-CGAGCTGCATGCTGTACATG-3’ 
Lck-Cre  5’-TCCTGTGAACTTGGTGCTTG-3’ 5’-AAAAGAAAACGTTGATGCCG-3’ 
PPAR
fl/fl  5’-CTCCAATGTTCTCAAACTTAC-3’ 5’-GATGAGTCATGTAAGTTGACC-3’ 
PTEN  5’-CTGTTCTAACCGGGCAGCTT-3’ 5’-CGTGTTGGAGGCAGGAGAAG-3’ 
 
4.1.5.  Equipment & Software 
Table 8: List of instruments 
Instruments&Software Provider 
AIDA Image Analyzer  Raytest GmbH (Straubenhardt) 
AutoMACS
TM Separator  Miltenyi Biotech GmbH (Bergisch-
Gladbach) 
AxioVision 40 V4.7.0.0 Software  Carl Zeiss AG (Jena) 
B250 Sonifier  Branson Ultrasonics (Danbury) 
CASY
® cell counter  Schärfe System (Reutlingen) 
Centrifuge 5415 R  Eppendorf GmbH (Hamburg) 
Centrifuge CR 3.22 and MR23i  Jouan GmbH (Unterhaching) 
CFX Cycler system  BioRad (Munich) 
CFX Manager Software  BioRad (Munich) 
FACS Diva Software  BD Bioscience (Heidelberg) 
FACSFortessa  BD Biosciences (Heidelberg) 
Flo Jo Software  Tree Star inc. (Ashland) 
Holten Lamin Air clean bench  Jouan GmbH (Unterhaching) 
IG 150 (cell culture incubator)  Jouan GmbH (Unterhaching) 
Mastercycler
®  Eppendorf GmbH (Hamburg) 
NanoDrop ND-1000  Peqlab Biotechnologie GmbH (Erlangen) 
Odyssey 2.1 Software  LiCOR Biosciences GmbH (Bad Homburg) 
Odyssey infrared imaging system  LI-COR Biosciences GmbH (Bad Homburg) MATERIAL AND METHODS     36 
Thermomixer 5436  Eppendorf GmbH (Hamburg) 
Trans-Blot SD blotting machine  BioRad (Munich) 
UV-Transilluminator gel documentation system  Raytest GmbH (Straubenhardt) 
Zeiss Axioskop 40  Carl Zeiss AG (Jena) MATERIAL AND METHODS     37 
4.2. Methods 
4.2.1. Mouse  work 
Genotyping of mice 
Conditional T-cell PPAR knockout (Tc-PPAR
-/-) mice were generated by 
crossing C57BL/6N mice, bearing loxP-flanked allels of PPAR (PPAR
fl/fl) (90), 
with C57BL/6NTac-(Tg) lck-Cre transgenic mice, in which the Cre recombinase 
has been knocked in behind the lck promoter (91-92). PPAR
fl/fl mice were used 
as control WT mice. 
Genotypes of mice were determined by PCR of tail genomic DNA. To prepare 
the genomic DNA, tail-tips (~0.5 cm) were cooked in 75 µl of lysis buffer (see 
Appendix), cooled down to room temperature and neutralized with 75  µl of 
neutralizing buffer (see Appendix). 3 µl were taken for PCR to analyze the 
expression of the Cre under control of the lck-promoter (lck-Cre primer) and the 
expression of loxP-sites in the PPAR gene (PPAR
fl/fl primer). 
Setup of genotyping PCR reaction: 
 
Enzyme activation        95 °C   15 min 
 
Denaturation      95  °C   15  s 
Annealing        55  °C   30  s 
Extension      72  °C     30  s 
 
PCR products were analyzed on 1.5 % agarose gels. 
 
 
Lipopolysaccharide (LPS)-induced systemic inflammation 
To induce systemic inflammatory conditions, WT mice and conditional Tc-PPAR
-/- 
mice were injected i.p. with 1 mg/kg lipopolysaccharide (LPS) from Escherichia coli, 
(serotype 0127:B8). After 24 h, mice were sacrificed and spleens were dissected. 
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Cecum ligation and puncture (CLP) sepsis model 
 
The cecum ligation and puncture (CLP) model was used to mimic septic 
conditions in mice. The CLP model has many pathophysiological similarities to 
the clinical situation where a bowel perforation-induced peritonitis results from 
an infection that is caused by mixed intestinal flora. The CLP model is one of 
the most widely used models of sepsis and septic shock. It satisfies many of the 
criteria for an appropriate sepsis model: it is polymicrobial, has focal infection 
origins, produces septicemia, and releases bacterial products into the periphery 
(93). 
 
 
 
Figure 9: Cecum ligation and puncture sepsis model. (A) After anesthetization, shaving, and 
desinfection, (B) the adomen of the mouse is opened and the cecum is exposed. Further, (C) 
the cecum is ligated, carefully not to disturb the ileocecal flow. (D) The ligated cecum is 
punctured once ‘through-and-through’ with a 20-gauge needle and (E) a small amount of faeces 
is extruded from each puncture site. At last, (F) the adominal cavity is closed in two layers. (G) 
The mouse receives 1 ml of 0.9% NaCl for fluid resuscitation as well as analgetics after the 
procedure and when needed and is monitored regularly. 
 
For CLP surgery, mice were anesthetized with 0.4 mg/kg ketamin (Ketavet
®) 
and 0.02 mg/kg xylazine (Rompun
®). The abdominal hairs were shaved and the 
area disinfected with 70% ethanol. The abdominal cavity is opened via a midline 
laparotomy incision of about 3 cm in an aseptic fashion and the cecum was 
exposed. The cecum is ligated distal to the ileocecal valve, taking care to 
maintain bowel continuity. The ligated cecum was punctured twice with a 20-MATERIAL AND METHODS     39 
gauge needle. Next, sufficient pressure was applied to the cecum to extrude a 
single droplet of fecal material from each puncture site. The abdomen is closed 
in two layers, and mice are resuscitated with 1 ml of 0.9% NaCl. Until mice 
wake up from narcosis they are kept warm on a heater mat. Mice subjected to 
sham laparotomy (sham) underwent the same procedure without ligation and 
puncture. Animals received s.c. 0.05  mg/kg buprenorphine (Temgesic
®) after 
surgery and in the following time as needed. Mice were sacrificed after 24 h or 
monitored regularly for seven days to determine survival (Figure 9). 
 
 
Antagonizing PPAR with GW9662 
To antagonize PPAR, WT mice were treated with 1 or 3 mg/kg GW9662. To 
verify the time point, when GW9662 exerts the most prominent effect, a time 
kinetic administrating GW9662 at 1 h, 3 h, or 5 h following CLP surgery was 
performed. 50 µl DMSO (10% in PBS) was supplied as solvent control. 
 
 
Neutralizing IL-2 
In vivo IL-2 neutralization was accomplished with an i.p. injection of 500  µg 
LEAF
TM purified anti-mouse IL-2 neutralizing antibody (anti-IL-2) 1 h post-CLP. 
To determine unspecific effects of the antibody, a control group was treated with 
500 µg LEAF
TM purified IgG isotype control antibody (IgG) 1 h after CLP. 
 
4.2.2.  Primary cell analysis 
T-cell isolation 
After 24  h following CLP surgery or LPS treatment, mice were sacrificed, 
spleens and blood were dissected and a single cell suspension of splenocytes 
was prepared. Whole blood and splenocytes were incubated for 5  min with 
erythrocyte lysing buffer (see Appendix), and subsequently centrifuged for 5 min 
at 4°C, 500 x g. T-cells were enriched to >90% by autoMACS separation from MATERIAL AND METHODS     40 
spleens using the Pan T-cell Isolation Kit. Therefore, splenocytes were counted 
using the Casy Counter. 1x10
8 cells were washed and suspended in 400 µl of 
running buffer (see Appendix). Next, cells were incubated with biotin-labeled 
antibodies against all cell populations besides T-cells for 10 min at 4°C (Pan T-
cell kit solution 1). Afterwards, 300 µl of running buffer and 200 µl of anti-biotin 
magnetic beads (Pan T-cell kit solution 2) were added and cells were incubated 
for 15 min at 4°C. Subsequently, the antibody-biotin-labeled cells were washed 
with 8  ml running buffer, centrifuged at 300  x  g for 5  min at 4°C and 
resuspended in 2 ml of running buffer. Isolation using the autoMACS separator 
was performed by negative isolation in the sensitive mode (<depletes>). The 
elution fraction was centrifuged at 300  x  g for 10  min and supernatant was 
discarded. Cells were resuspended in 10 ml of running buffer and counted using 
the Casy Counter. After another centrifugation at 300 x g for 10 min, the cell 
pellet was frozen at -20°C for subsequent protein or mRNA isolation as 
described. Purification was verified by FACS analysis using an anti-CD3ε-FITC-
labeled antibody. 
 
 
FACS analysis 
Splenocyte suspensions were prepared from freshly dissected spleens following 
standard procedures. Incubating cell suspensions for 5 min with erythrocytes 
lysis buffer (see Appendix) lysed erythrocytes. 10
6 cells were incubated with 
fluorophore-conjugated antibodies against the following cell-surface proteins: 
anti-CD45-pacific blue, anti-CD4-PE, anti-CD3ε-FITC, and anti-CD8a-APC for 
30  min at 4°  C in PBS, 0.5%  BSA. Following incubations, labeled cells were 
washed with PBS. 15  min prior to analysis with FACSFortessa, cells were 
incubated with Nuclear ORANGE to mark living cells. For analysis of specific 
cell populations, gates were set with appropriate controls. 
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Intracellular IL-2 analysis 
To analyze intracellular levels of IL-2, 10
6 splenic T-cells were suspended in 
500 µl culture medium. Cells were incubated for 2.5 h with 50 µM brefeldin A to 
block anterograde protein transport. The reaction was stopped with 50  µl of 
20 mM EDTA. Next, cells were stained with antibodies to cell-surface proteins 
as described. Subsequently, cells were fixed in 3% PFA at room temperature 
for 30  min and afterwards permeabilized with 1% NP-40 for 1  h. To prevent 
unspecific binding, cells were blocked with 1% BSA for 20 min before staining 
with anti-IL-2-PE on a rotating platform in the dark at 4°C for 1 h. Intracellular  
IL-2 was visualized using FACS analysis. FACS Diva software and Flow Jo 
Software were used for analysis. 
 
4.2.3.  Biochemistry and molecular biology 
Chromatin immunoprecipitation (ChIP) assay 
ChIP assay was performed with 1x10
7 primary T-cells derived from sham or 
CLP mice with different treatments. Cells were resuspended in 5 ml culture 
medium, crosslinked by adding 45  µl 37% formaldehyde/ml and shaked at 
200 rpm for 5 min at RT. Afterwards, 80 µl 1 M glycine/ml medium was added 
and incubated for another 5 min with shaking. Cells were washed with PBS and 
resuspended in 1  ml ChIP lysis buffer (see Appendix) directly followed by 
centrifugation for 1  min at 4°C at 12,000 x g.  Sedimented  nuclei  were 
resuspended in 400 µl ChIP lysis buffer and incubated for 15 min on ice. To 
shredder whole genomic DNA, glass beads were added to the lysate and 
sonicated three fold with 18 x 8 pulses. To determine DNA fragmentation and 
for input control, the sonicated lysate was analyzed by agarose gel 
electrophoresis. 120 µl of each lysate containing fragmented soluble chromatin 
was immunoprecipitated with 2 µg of anti-NFAT antibody. For mock-IP, lysates 
were incubated with 1 µg of normal rabbit IgG over night at 4°C on a rotating 
platform. 50 µl of protein G agarose beads were preincubated with 5 µl salmon 
testes DNA (10.6 mg/ml) and 25 µl BSA (10 mg/ml). The next day 10 µl of PIM 
was added. 30  µl of prepared protein G agarose beads were added to the MATERIAL AND METHODS     42 
immunoprecipitated probe and incubated over night at 4°C on a rotating 
platform. To wash away non-bound proteins, agarose beads were washed   
5 times with 1  ml ChIP lysis buffer followed by centrifugation for 1  min at 
2,000 x g.  Afterwards,  100 µl  Chelex  100 were added, briefly vortexed and 
boiled at 99°C for 10 min. To digest proteins, 1 µl of proteinase K (20 µg/ml) 
was added and incubated at 37°C for 1 h followed by another 10 min at 99°C. 
Tubes were then centrifuged for 1 min at 12,000 x g. To finally isolate the DNA, 
80 µl of elution buffer (EB) were added, vortexed for 10 sec and centrifuged for 
1 min at 12,000 x g. The isolation step was repeated and supernatants were 
combined in a new tube. DNA was extracted using the PCR Purification Kit from 
Qiagen. Therefore, supernatants were precipitated with 5 volumes of 
precipitation buffer (including ethanol). Precipitation was performed for at least 
30 min at 4°C or over night at -20°C. The precipitated sample was applied to a 
purification column and centrifuged for 1 min at 12,000 x g. After washing the 
column 3 times with precipitation buffer, the DNA is eluted. Therefore, 200 µl 
elution buffer was prewarmed to 50°C and 100 µl were put on the column, let 
stand for 1 min and centrifuged at 12,000 x g for 1 min. The eluation step was 
repeated with another 100  µl elution buffer. A 423-bp fragment of the IL-2 
promoter spanning an established NFAT response element (94) was amplified 
using 5 µl of DNA and the ChIP-IL-2 primer. For input controls 20% fragmented 
DNA of each probe was used. Resulting fragments were separated on a 1.5% 
agarose gel containing ethidium bromide (0.5 mg/l). Bands were visualized by 
UV excitation. 
 
 
RNA isolation, reverse transcription and realtime PCR 
Primary T-cells were isolated from spleens as described. Total RNA from T-
cells was isolated using PeqGold RNAPure following manufacturer’s 
description. In brief, 1 ml of PeqGold was applied to 5x10
6 cells. After 10 min 
incubation the lysate was transferred to 1.5 ml vials, supplemented with 200 µl 
chloroform and mixed thoroughly for 15 s. The mixture was incubated for 5 min 
at room temperature, followed by 5 min centrifugation with 12,000 x g at room 
temperature. During this step, the mixture separated into a chloroform phase, MATERIAL AND METHODS     43 
and a water phase, divided by a small phase with debris. The upper water 
phase was transferred to a fresh 1.5 ml vial, was mixed with 500 µl isopropanol 
and incubated 30  min at room temperature for RNA precipitation. RNA was 
sedimented by centrifugation (15 min, 12,000 x g, 4°C) and washed twice with 
1 ml 70% ethanol in DEPC-treated distilled H2O. The RNA pellet was air dried 
at 60°C and resuspended in DEPC-treated distilled H2O. RNA concentration 
was determined with the NanoDrop ND-1000. 
Reverse transcription was performed with 1  µg RNA using iScript cDNA 
synthesis kit. In brief, 1 µg of isolated mRNA was mixed with 4 µl 5x reaction 
buffer, 1 µl iScript reverse transcriptase and filled up with nuclease-free H2O to 
20 µl. The reaction mix was incubated for 5 min at 25°C, 30 min at 42°C and 
finally 5 min at 85°C for enzyme inactivation. The resulting cDNA was diluted 
1:5. 
Quantitative PCR was performed with Absolute QPCR SYBR Green mix 
according to manufacturer’s instructions. 4 µl of cDNA were mixed with either 
1 µl QuantiTect Primer Assay or 0.5 µl forward and reverse primer (5 µM) each, 
10 µl Absolute™ qPCR SYBR Green Fluorescein Mix and filled up with distilled 
H2O to 20 µl. The mixtures were transferred to a 96-well plate, spinned down 
and the plate sealed with an optical adhesive seal sheet. qPCR was performed 
using the MyiQ Single-Colour Real-time PCR Detection System and the 
following thermal cycling program: 
 
Enzyme activation        95 °C   15 min 
Denaturation      95  °C   15  s 
Annealing        55  °C   30  s 
Extension      72  °C     30  s 
 
To confirm the specificity of the reaction, a melt curve was created using the 
following program: 
 
Denaturation      95  °C   30  s 
Starting temperature      60 °C   30 s 
Melting  step      60  °C     10  s 
         +  0.5°C  per  cycle 
45 cycles 
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Relative mRNA expression was calculated using the BIO-RAD GeneEx gene 
expression macro based on the ddCt method. 
 
 
Protein determination (Lowry) and SDS-PAGE/Western blot (WB) analysis 
For Western analysis, primary mouse T-cells were isolated as indicated, 
pelleted by centrifugation and resuspended in 100-200 µl Urea Lysis Buffer (see 
Appendix) and sonicated. After shaking the lysate for 30 min at 4°C, the lysate 
was cleared by centrifugation (15,000  x  g, 15  min, 4  °C). The protein 
concentration was determined using DC Protein Assay Kit, based on the Lowry 
method. Briefly, a standard dilution series of bovine serum albumin (BSA) in 
Urea Lysis Buffer was prepared (0.625 to 10 mg/ml). 2 µl of the samples and 
the standard dilutions were pipetted in duplicates into a 96-well plate, 20 µl of 
solution A, and 160 µl of solution B were added. The colorimetric reaction was 
detected after incubation for 10  min at RT with shaking. The extinction was 
measured at 750  nm using the Mithras LB 940 multimode reader. 80  µg of 
protein were denatured using 4 x sample buffer (see Appendix) and resolved on 
10% SDS-polyacrylamide gels (see Appendix). Proteins were blotted onto 
nitrocellulose membrane, blocked with Rockland Blocking Buffer for IRDye 
Fluorescence Western Blotting and treated with primary antibodies in Blocking 
Buffer/50% TTBS (see Appendix). After overnight incubations at 4°C 
membranes were washed 3 times for 5 min with TTBS. For protein detection, 
blots were incubated with IRDye800CW-labeled secondary antibody for 45 min 
and washed 3 times for 5 min each with TTBS. Detection was performed using 
Odyssey Infrared Imaging System. Densitometry of the Western blots was 
performed using the LI-COR Odyssey 2.1 software. 
 
 
TUNEL Assay 
TUNEL assay was performed according to the manufacturer’s instructions using 
the APO-BRDU TUNEL kit. 10
6 freshly isolated splenocytes were labeled with 
anti-CD3ε-APC for 30 min in 100 µl PBS. Afterwards, cells were fixed in 1 ml MATERIAL AND METHODS     45 
1% PFA for 1 h, washed with 1 ml PBS and resuspended in 1 ml 70% (v/v) 
ethanol. Cells were stored at -20°C until experiments were performed. For 
labeling of apoptotic cells, cells were incubated with Br-dUTP for 60  min at 
37°C, followed by 30 min incubation with the FITC-labeled secondary antibody. 
To label total cellular DNA propidium iodide (PI) dye was supplied 15 min before 
analysis by flow cytometry using the FACSFortessa. 
 
 
Immunhistochemistry 
Spleens were collected and fixed in zinc fixation buffer (see Appendix) for 6 h at 
room temperature. Next, tissue was dehydrated in a graded ethanol series and 
embedded in paraffin. Paraffin sections were processed with standard histology 
procedures using the catalyzed signal amplification kit according to the 
manufacturer´s instructions. In brief, 4 µm paraffin-embedded sections were 
deparaffinized, rehydrated in a graded ethanol series and washed in PBS. For 
antigen retrieval sections were soaked in target retrieval solution (TRS) and 
cooked for 10 min. Slides were washed, blocked and stained with rabbit anti-
cleaved caspase 3 antibody in antibody diluent over night at 4°C. Next, slides 
were incubated with a biotinylated anti-rabbit antibody for 1  h, followed by 
incubation with 0.5% H2O2 in PBS for 15 min to block endogenous peroxidase 
activity. Further, sections were incubated with horseradish peroxidase-
conjugated anti-biotin for 15 min. For color development, 3,3´-diaminobenzidine 
tetrahydrochloride (DAB) chromogen was used and counterstained with Mayer’s 
hematoxyllin (1:10) and Eosin G (H&E). Sections were analyzed using the Zeiss 
Axioskop 40 with the AxioVision 40 V4.7.0.0 Software. The magnification of 
images shown is 100 x. 
 
 
In vivo PPRE reporter analysis 
3x10
6 HEK293T cells were seeded in 5 ml DMEM high glucose medium on a  
10 cm cell culture dish. The next day, transfection was performed using 6 µl 
JetPei and 200 µl 150mM NaCl in combination with 3 µg of the versatile HIV-MATERIAL AND METHODS     46 
based PPRE lentivector plasmid that co-expresses mRuby and Firefly 
Luciferase in response to PPRE activation, 26 µl lentiviral packaging mix and 
200 µl NaCl. After 2 days, the medium was changed. Another 3 days later, the 
supernatant medium contains lentiviruses with the PPRE reporter plasmid. 
For in vivo PPRE reporter experiments, T-cells were isolated from GFP
+/+ mice. 
Next, GFP
+/+ T-cells cells were transduced with the lentiviruses containing the 
PPRE reporter plasmid by two centrifugations for 100  min at 300  x  g. After 
transduction, cells were washed four times with 10 ml PBS, diluted in 200 µl of 
sterile 0.9% NaCl and injected into the tail vein of WT mice. 36 h later, mice 
were subjected to CLP with subsequent treatment with 1 mg/kg GW9662 at 3 h 
or left untreated. After 24  h, mice were sacrificed and blood T-cells were 
analyzed by flow cytometry. Lymphocytes were gated for CD3
+ cells and GFP
+/+ 
cells. In the GFP
+/+ population, mRuby expression was quantified, which mirrors 
PPRE reporter activation. 
 
4.2.4. Microbiology 
Bacteriologic analysis of peritoneal lavage 
After sacrificing mice 24 h after CLP, the peritoneum was washed with 4 ml of 
Thioglycollate-M solution. A dilution series of 1:10, 1:100, 1:1000 with PBS was 
produced. 100 µl of each dilution was plated on either Columbia-Agar plates or 
Endo-Agar plates for gram-positive or gram-negative bacterial colony detection, 
respectively. After cultivation for 24 h at 37°C, gram-negative and gram-positive 
colony-forming-units (CFU) were counted for each dilution, multiplied with the 
dilution factor and displayed as CFU/100µl peritoneal lavage. Bacterial load 
measurements were performed by Prof. Dr. Volkhard Kempf of the Institute of 
Microbiology and Infection Control, Goethe-University Frankfurt. 
 
4.2.5. Statistical  analysis 
All data are expressed as means ± SD and each experiment was performed at 
least three times. Statistical significance was determined by unpaired student´s MATERIAL AND METHODS     47 
t-test or the fisher´s exact P-test. For Western analysis, ChIP analysis, and 
immunohistological stainings representative data of at least three independently 
performed experiments are shown. Differences were considered significant if: 
*p<0.05; **p<0.01; ***p<0.001. RESULTS     48 
5. RESULTS 
5.1. Phenotyping  Tc-PPAR
-/- mice 
I first investigated whether the newly generated conditional T-cell PPAR 
knockout mice (Tc-PPAR
-/-) have sufficient ablation of PPAR in T-cells. 
Isolated T-cells of Tc-PPAR
-/- mice express significantly lower PPAR mRNA 
and protein as WT mice (Figure 10). For T-cells it was shown that PPAR 
expression is induced upon activation, such as upon sepsis (95). However, 
even under septic conditions provoked by CLP, PPAR protein expression is 
not upregulated in Tc-PPAR
-/-, whereas the protein is highly abundant in WT 
mice during septic conditions (Figure 10B). 
 
 
 
Figure 10: PPAR expression in T-cells derived from WT or Tc-PPAR
-/- mice. (A) Real-time 
PCR analysis of PPAR mRNA expression. PPAR expression in WT T-cells was set to 100%. 
Data is shown as mean ±SD. (B) Western analysis of PPAR protein expression in T-cells 
derived from 24  h sham- or CLP-treated mice. Data are representative of at least three 
independent experiments. ***p<0.001. 
 
These data proved PPAR to be sufficiently ablated in T-cells by genetic 
depletion of the PPAR gene using loxP flankation and Cre expression upon 
lck-promoter activation in T-cells. 
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5.2. LPS-induced  systemic inflammation in Tc-PPAR
-/- vs. WT 
mice 
To examine the effects of PPAR in T-cells during systemic inflammation, I 
challenged WT and Tc-PPAR
-/- mice with i.p. injection of 1 mg/kg LPS. 24 h 
thereafter mice were sacrificed and analyzed for relative splenic T-cell count. As 
seen in Figure 11A, I noticed severe T-cell depletion in the WT group after LPS, 
whereas in Tc-PPAR
-/- spleens, the T-cell count was not affected by LPS. 
Moreover, after isolation of splenic T-cells I questioned whether apoptotic 
signals regulated by important cell death regulating proteins are differently 
expressed in T-cells with or without PPAR. At first, I analyzed expression levels 
of the most prominent T-cell survival factor, namely IL-2. IL-2 is expressed by T-
cells and autocrine IL-2 receptor activation promotes T-cell proliferation and cell 
cycle control. I recognized an increased expression of IL-2 mRNA in the Tc-
PPAR
-/- population (Figure 11B).  A downstream target of autocrine IL-2 
receptor stimulation is the anti-apoptotic protein Bcl-2. When determining 
expression levels of anti-apoptotic Bcl-2 mRNA I recognized again a strong 
increase in the Tc-PPAR
-/- group, whereas WT mice showed no upregulation 
(Figure 11B). As a pro-apoptotic protein, the Bcl-2 family member Bim was 
previously shown to be upregulated during sepsis and is specifically highly 
expressed in T-cells during sepsis, and its knockout provoked better survival of 
septic mice (88). Thus, I investigated Bim expression levels. In my model using 
LPS-treated WT and Tc-PPAR
-/-  mice, I proved pro-apoptotic Bim mRNA 
expression to be decreased in isolated T-cells derived from LPS-stimulated Tc-
PPAR
-/- in contrast to T-cells from WT mice (Figure 11B). This result proposes 
that WT mice treated with LPS contain induced apoptotic signals in their T-cells, 
which correlates to lower T-cell counts compared to mice with genetical ablation 
of PPAR. 
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Figure 11: LPS-induced T-cell depletion and underlying apoptotic signals. (A) Relative T-cell 
count in Tc-PPAR
-/- (white bars) and WT (black bars) mice 24 h after LPS or without treatment. 
T-cell counts in untreated controls were set to 100%. (B) X-fold induction of mRNA expression 
of IL-2, Bcl-2 and Bim relative to untreated controls detected by real-time PCR. Graphs show 
mean values ± SD. 
*p<0.05; 
**p<0.01; 
***p<0.001; N.S., not significant. 
 
Inducing systemic inflammation with LPS does not represent a high clinical 
relevance thus, in order to further verify importance of PPAR during sepsis 
progression I decided to continue my research using an animal model of sepsis 
with great similarities to human sepsis pathophysiology. 
 
 
5.3.  CLP-induced sepsis in Tc-PPAR
-/- vs. WT mice 
5.3.1. Absolute  T-cell  count 
Additionally to the LPS model, I used the cecum ligation and puncture (CLP) 
model to mimic septic conditions in mice. This model closely resembles the 
situation of a ruptured abdominal anastomosis leading to sepsis in humans (96) 
and is described in detail in 4.2.1. Previous studies have shown that T-
lymphocyte depletion was most prominent at 24  h following CLP (97). To 
characterize differences during sepsis progression of WT and Tc-PPAR
-/- mice 
subjected to CLP, I evaluated the amount of viable T-cells in the spleen and 
blood 24 h after CLP. As seen in Figure 12, FACS analysis of T-cell populations 
in the spleen and blood showed a marked decrease in T-cell numbers of WT 
animals. Regarding T-cell subpopulations, especially the CD4
+ cell count was 
reduced in blood and spleens, whereas the CD8
+ cell count was only reduced in 
blood. In contrast, T-cells in spleens of Tc-PPAR
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compared to sham-operated controls. In blood, CD4
+ as well as CD8
+ cells 
even increased in number. Interestingly, in untreated Tc-PPAR
-/- mice, I 
detected lower T-cell counts in the spleen and in the blood (Figure 12). This 
phenotype suggests PPAR to be involved in T-cell development. 
 
 
 
Figure 12: Flow cytometric quantification of spleen and blood derived T-cells and 
subpopulations from WT and Tc-PPAR
-/- mice at 24 h post CLP compared to sham controls. 
For identification, cells were stained with anti-CD3ε, anti-CD4, as well as anti-CD8a and co-
stained using anti-CD45 and Nuclear ORANGE to detect living lymphocytes. Data are means 
± SD. 
*p<0.05; 
**p<0.01; 
***p<0.001; N.S., not significant. 
 
5.3.2.  Detection of apoptotic T-cells 
To analyze whether decreased T-cell counts are provoked by increased 
apoptosis in the spleen, I established two methods to detect different apoptosis 
markers. First, I identified apoptosis by histological analysis staining active 
caspase 3 in spleens. These experiments revealed that at 24 h following CLP, 
apoptotic cells accumulated in the T-cell enriched white pulp (WP) of WT mice 
spleens, whereas almost no splenocytes of Tc-PPAR
-/- contained active 
caspase 3 (Figure 13A). Although caspase activation is often assumed to be 
synonymous with cell death, they are multifunctional enzymes that convey a RESULTS     52 
number of actions, including regulation of lymphocyte proliferation, 
differentiation and cell cycle regulation (29, 76). Thus, the fact that there is an 
increase in caspase activation does not a priori signify that lymphocytes are 
undergoing apoptosis. In the present case, however, there is additional 
evidence that strongly suggests that the increased caspase 3 activation results 
in cell death. The staining of the degradation of intact chromatin structures into 
DNA fragments (TUNEL staining), determined by flow cytometry analysis, 
envisions an important hallmark of apoptosis. Septic T-cells from WT mice 
presented significantly more TUNEL positive cells compared to Tc-PPAR
-/- T-
cells (Figure 13B). Thus, it is likely that caspase activation in the setting of 
sepsis is indicative of its role in cell death. 
 
 
 
Figure 13: Apoptosis detection in septic Tc-PPAR
-/- mice and WT mice by caspase 3 staining 
and TUNEL assay. (A) Histological analysis of CLP-induced splenocyte apoptosis. Spleen 
sections were stained for active caspase 3 (brown) and counterstained with H&E (red and blue). 
Dashed line surrounds T-cell enriched white pulp (WP). RP, red pulp. Data are representative 
for at least three independent experiments. Scale bars=100 µm.
 (B) Quantification of apoptotic 
T-cells in spleens by anti-CD3ε and TUNEL staining using flow cytometry. Values are 
expressed as a mean percentage ± SD of apoptotic T-cells relative to the total amount of T-cells 
in spleens of sham or CLP-treated mice. 
***p<0.001; N.S., not significant. 
 
5.3.3. Survival  studies 
Next, survival of septic mice observed for 7 days should clarify the question, 
whether increased T-cell counts in Tc-PPAR
-/- mice account for better survival. 
As seen in Figure 14, no WT mouse survived 7 days of severe septic conditions RESULTS     53 
initiated by CLP, whereas 60% of the Tc-PPAR
-/- mice survived the observation 
time. Statistical analysis approved the survival advantage of the knockout 
population to be significant at 7 days after CLP. Previous investigations 
confirmed this result demonstrating a 100% mortality of WT mice occurring in 4 
days if >30% of the cecum is ligated (same in our model) and a double puncture 
with a 20-gauge needle is performed (93).  
 
 
 
Figure 14: Survival curves of CLP-induced death of WT and Tc-PPAR
-/- mice observed for 7d. 
**p<0.01. 
 
These differences in survival support my assumption that PPAR exerts 
apoptosis of T-cells during sepsis thus, reducing survival during peritonitis-
induced sepsis. 
 
Next, I aimed at elucidating how this increased T-cell count contributes to 
improved survival. Therefore, the potential of T-cells to affect other cells, such 
as phagocytes, and to improve the bacterial clearance was assessed by 
peritoneal colony formig units (CFU) counts of CLP-treated mice. The peritoneal 
cavity contains multiple microbes that can be cultured, such as Escherichia coli, 
Proteus mirabilis, Enterococcus, Bacteroides fragilis, etc. (93). When analyzing 
the kind and amount of bacteria found in the peritoneum, I discovered higher 
levels (not significant) of gram-positive as well as gram-negative bacteria in WT 
mice, compared to Tc-PPAR
-/- mice (Figure 15A). To detect whether this result 
also accounts for less organ damage and thus, decreases mortality, specific 
organ damage markers in the serum were envisioned. In my experiments, these 
markers were aspartate aminotransferase (AST, a nonspecific marker for 
hepatic injury), alanine aminotransferase (ALT, a specific marker for hepatic RESULTS     54 
parenchymal injury) and lactate dehydrogenase (LDH, unspecific organ damage 
marker) (98-99). AST, ALT and LDH were significantly increased in WT mice 
and mirror the poor survival of these mice in comparison to Tc-PPAR
-/- mice 
(Figure 15B). 
 
 
 
Figure 15: Bacterial load and end organ damage in CLP-treated WT and Tc-PPAR
-/- mice after 
24 h. (A) Gram-negative and gram-positive bacterial load in peritoneum of mice. After sacrificing 
the mice, their peritonea were washed with 4 ml thioglycollate-G solution. Data shown are gram-
positive and gram-negative bacteria colony forming units (CFU) in 100 µl of peritoneal lavage 
fluid. (B) Serum activities of lactate dehydrogenase (LDH), alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) in mice subjected to CLP or sham. Data are means ± SD. 
*p<0.05; 
**p<0.01. 
 
5.3.4. Apoptotic  signaling in WT vs. Tc-PPAR
-/- T-cells 
Modification of the pro-survival NFAT/IL-2/Bcl-2 pathway 
To outline the molecular pro-survival effect of PPAR deficiency, I investigated 
whether the ability of PPAR to repress cytokine production in T-cells during 
sepsis accounts for increased apoptosis. IL-2 is known to be the most relevant 
cytokine for T-cell survival by increasing the expression of anti-apoptotic 
proteins, including Bcl-2 (100-101). IL-2 gene expression is transcriptionally 
regulated by nuclear factor of activated T-cells (NFAT), but complex formation 
with active PPAR inhibits NFAT interaction with DNA (60, 102). 
Therefore, I propose that in my model PPAR inhibits IL-2 expression by 
binding to NFAT and consequently limits anti-apoptotic Bcl-2 signaling. To 
prove this assumption, I first examined IL-2 expression in splenic T-cells. I 
found elevated IL-2 mRNA expression in Tc-PPAR
-/- cells, but not in WT T-RESULTS     55 
cells (Figure 16A). Since IL-2 protein is mainly but not exclusively secreted by 
T-cells (103), I next analyzed T-cell-specific IL-2 formation by intracellular IL-2 
staining instead of analyzing serum levels of IL-2. In correlation with the 
detected mRNA quantity, the amount of intracellular IL-2 was as well 
significantly higher in cells of Tc-PPAR
-/- mice compared to cells of WT mice 
after CLP (Figure 16B). As referred to in 3.2.4 and mentioned above, the 
PPAR protein is able to bind other transcription factors and indirectly inhibits 
their transcriptional potential (mechanism of transrepression). Thus, diminished 
IL-2 mRNA expression can result from PPAR ligating the transciption factor 
NFAT and thus, preventing IL-2 transcription (102). This ligation can be 
visualized and quantified by the amount of (unligated) NFAT binding to the IL-2 
promoter in T-cells. A method that is capable of quantifying protein-DNA 
interaction is the chromatin immunoprecipitation (ChIP) assay. Using this 
method, I observed enhanced NFAT binding to the IL-2 promoter in Tc-PPAR
-/- 
T-cells, but none in WT T-cells after peritonitis induction or under unstimulated 
conditions (Figure 16C). 
 
 
 
Figure 16: IL-2 mRNA expression, intracellular IL-2 protein expression and binding of NFAT to 
the IL-2 promoter in T-cells from WT and Tc-PPAR
-/- mice. Mice were sacrificed after 24 h 
following CLP or sham surgery. Spleens were dissected and T-cells were isolated. (A) Relative 
IL-2 mRNA expression in T-cells related to WT sham expression levels. (B) Intracellular IL-2 
protein amount in T-cells. Percentage values indicate IL-2 expressing T-cells. (C) Association of 
NFAT with its response element within the IL-2 promoter analyzed by ChIP analysis. IgG was 
used to identify unspecific binding of the antibody. Data are representative of at least three 
independent experiments. 
**p<0.01; N.S., not significant. 
 
Hotchkiss et al. described that overexpression of anti-apoptotic proteins, such 
as Bcl-2, prevents lymphocyte cell death during sepsis and improves survival of 
septic mice (80). Taking this report into consideration, I quantified Bcl-2 RESULTS     56 
expression as downstream target of IL-2 receptor stimulation during 
polymicrobial sepsis. Similar to the results of the LPS-model shown in 
Figure 11, I herein display a significant anti-apoptotic Bcl-2 mRNA induction in 
Tc-PPAR
-/- T-cells for the CLP model as well. In contrast, Bcl-2 mRNA was not 
induced in WT mice (Figure 17A). To check whether this is also true for the 
resulting Bcl-2 protein, I performed Western analysis. Importantly, Bcl-2 protein 
levels increased in Tc-PPAR
-/- after CLP in contrast to WT T-cells (Figure 17B). 
 
 
 
Figure 17: Bcl-2 mRNA and protein expression in septic WT and Tc-PPAR
-/- mice. Mice were 
sacrificed after 24 h following cecum ligation and puncture (CLP) or sham surgery. Spleens 
were dissected and T-cells were isolated. (A) Relative Bcl-2 mRNA expression in T-cells related 
to WT sham expression levels. Values are the means ±  SD of at least three independent 
experiments. (B) Western analysis of Bcl-2 expression in T-cells. 
**p<0.01; N.S., not significant. 
 
 
5.4. Neutralizing IL-2 impairs pro-survival signaling in Tc-
PPAR
-/- 
The above mentioned experiments present an IL-2-dependent Bcl-2 protein 
expression in Tc-PPAR
-/- mice, however, the final prove for this apoptosis 
pathway in PPAR-lacking mice is still missing. A prove would be given if 
“overproduced” IL-2 is neutralized in Tc-PPAR
-/- mice, making them, in regard 
to IL-2 expression, similar to WT mice. Less pro-survival IL-2 receptor signaling, 
should then in turn also repress Bcl-2 and hence, reverse the pro-survival 
effects associated with increased IL-2 expression as described for Tc-PPAR
-/- 
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The IL-2 neutralizing antibody (anti-IL-2) strongly reduced the count of Tc-
PPAR
-/- T-cells in spleens and blood of Tc-PPAR
-/- mice after CLP compared 
to application of an isotype control (IgG). Especially CD4
+ T-cells decreased, 
whereas CD8
+ cells were only slightly reduced in peripheral blood (Figure 18). 
 
 
 
Figure 18: Absolute T-cell count in spleens and blood of anti-IL-2 or IgG-treated Tc-PPAR
-/- 
mice. Mice received either 500 µg anti-IL-2 or 500 µg IgG control antibody (IgG) at 1 h after 
CLP. Tc-PPAR
-/- sham mice were used as controls. T-cell quantification in spleen and blood 
was performed using flow cytometry. T-cells were stained with anti-CD3ε, anti-CD4, as well as 
anti-CD8a and co-stained using anti-CD45 and Nuclear ORANGE to detect living lymphocytes. 
Values are the means ± SD. 
*p<0.05; N.S., not significant. 
 
Also for the experimental setup neutralizing IL-2, I aimed at proving that the T-
cell count correlates with apoptosis. Apoptosis detection (as previously 
performed) should clarify if anti-IL-2 depleted T-cells are dying by apoptosis. 
Anti-IL-2 treated mice presented an increase in TUNEL-positive (Figure 19A) 
and active caspase 3-positive T-cells (Figure 19B) after CLP. Antibody control 
(IgG) treatment did not exhibit apoptosis of splenic T-cells. IgG treatment 
provoked similar apoptosis patterns as untreated Tc-PPAR
-/- mice. 
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Figure 19: Evaluation of apoptosis by TUNEL and active caspase 3 staining in anti-IL-2 and 
IgG-treated Tc-PPAR
-/- mice. Mice received either 500  µg anti-IL-2 or 500  µg IgG control 
antibody (IgG) at 1 h after cecum ligation and puncture (CLP). Tc-PPAR
-/- sham mice were 
used as controls. (A) Quantification of apoptotic T-cells in spleens using anti-CD3ε and TUNEL 
staining by flow cytometry. Values are expressed as the mean percentage ± SD of apoptotic T-
cells of total T-cell amounts in spleens. (B) Histological analysis of CLP-induced splenocyte 
apoptosis. Spleen sections were stained for active caspase 3 (brown) and counterstained with 
H&E (blue and red). Dashed line surrounds T-cell-enriched white pulp (WP). RP, red pulp. 
**p<0.01. N.S., not significant. 
 
If the lower T-cell count referred to in Figure 18 provokes less survival, anti-IL-2-
treated mice should have a higher mortality rate compared to IgG-treated mice. 
I observed a poor 7-day survival upon anti-IL-2 treatment (10%) compared to 
IgG-treated littermates (60%) (Figure 20). 
 
 
 
Figure 20: Comparison of survival of anti-IL-2-treated and IgG-treated Tc-PPAR
-/- mice. Mice 
received either 500 µg anti-IL-2 or 500 µg IgG control antibody (IgG) at 1 h after CLP. Survival 
of mice was observed for 7d. 
*p<0.05. 
 
As shown for WT and Tc-PPAR
-/- mice, I next questioned whether lower T-cell 
counts detected upon anti-IL-2 treatment correlate with lower bacterial 
clearance and higher end organ damage. Anti-IL-2 treatment tended to exhibit RESULTS     59 
more gram-negative and gram-positive CFU as antibody control treament 
Figure 21A). In line, lower T-cell counts pointed to worse end organ damage as 
indicated by LDH, AST, and ALT (Figure 21B). 
 
 
 
Figure 21: Bacterial clearance and end organ damage in anti-IL-2 and IgG-treated Tc-PPAR
-/- 
mice. (A) Gram-negative and gram-positive bacterial load in peritoneum of mice. After 
sacrificing the mice, their peritonea were washed with 4 ml thioglycollate-G solution. Data 
shown are gram-positive and gram-negative bacteria colony forming units (CFU) in 100 µl of 
peritoneal lavage fluid. (B) Serum activities of lactate dehydrogenase (LDH), alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) in mice subjected to CLP or 
sham. Data are means ± SD. 
 
If IL-2 receptor stimulation provokes Bcl-2 expression, this anti-apoptotic protein 
should be expressed less in anti-IL-2 treated mice. Bcl-2 mRNA (Figure 22A) 
and protein expression (Figure 22B) were diminished upon neutralizing IL-2 in 
Tc-PPAR
-/- mice when compared to IgG-treated controls. 
 
 
 
Figure 22: Bcl-2 mRNA and protein expression in anti-IL-2 and IgG-treated Tc-PPAR
-/- mice. 
Mice received either 500 µg anti-IL-2 or 500 µg IgG control antibody (IgG) at 1 h after cecum 
ligation and puncture (CLP). Tc-PPAR
-/- sham mice were used as controls. 24 h later, mice RESULTS     60 
were sacrificed, spleens were harvested and T-cells were isolated. Values are the means ± SD. 
**p<0.01. (A) Fold induction of Bcl-2 mRNA detected by real-time PCR and (B) Bcl-2 protein 
expression in T-cells detected by Western analysis. 
 
 
Modification of the PTEN/PI3K/Akt pathway 
So far, I was able to confirm a PPAR-dependent apoptosis that is initiated by 
reduced transcription of IL-2 by NFAT. However, there is another highly 
important molecular pathway that has a great impact on apoptosis with a so far 
unclear, but possible influence of PPAR. This is the PI3K/Akt pathway, which 
modifies cell survival i.e. by regulation of pro-apoptotic Bim. Upstream of Akt, 
the tumor suppressor protein PTEN inhibits PI3K signaling by its lipid 
phosphatase activity, dephosphorylating phosphatidylinositol-triphosphate 
(PIP3), which impairs Akt phosphorylation (104-105). Phosphorylated Akt (pAkt) 
counteracts apoptosis and induces proliferation (106-107). A PPAR responsive 
element was detected in the PTEN promoter region previously (105). 
Consequently, PPAR-induced PTEN stalls cell division and causes cells to 
undergo programmed cell death. Therefore, I investigated PPAR-dependent 
PTEN expression and downstream signaling in my experimental model of 
sepsis. PTEN expression was upregulated in septic T-cells from WT mice, 
whereas Tc-PPAR
-/- T-cells showed no induction (Figure 23A). Subsequently, 
PTEN activation inhibits the PI3K pathway thus, lowering Akt phosphorylation 
(pAkt) after CLP in WT T-cells. Knockout of PPAR abolished this effect and 
increased Akt phosphorylation (Figure 23B). 
 
 
 
Figure 23: PTEN and pAkt expression in WT and Tc-PPAR
-/- mice. Mice were sacrificed after 
24 h following CLP or sham surgery. (A) PTEN mRNA expression detected in T-cells of WT and RESULTS     61 
Tc-PPAR
-/- mice after CLP with real-time PCR. Values are the means ± SD. ***p<0.001. N.S., 
not significant. (B) Western analysis of phosphorylated Akt (pAkt) in WT vs. Tc-PPAR
-/- mice.  
 
One major target gene that is expressed following an inhibition of the PI3K/Akt 
pathway is the pro-apoptotic BH3-only protein Bim. Bim activation and 
apoptosis induction in T-cells is established and considered as one of the most 
critical pathogenic mechanisms in sepsis (88, 108-109). In line, the delivery of 
siRNA to Bim during sepsis resulted in an increased survival of mice, due to an 
inhibition of T-cell apoptosis (88). Having shown that PPAR induces PTEN 
expression and inhibits downstream pAkt, therefore I proceeded my research 
with examining the expression of pro-apoptotic Bim in T-cells. I noticed that Bim 
protein and mRNA were induced in T-cells of WT mice, whereas its expression 
in Tc-PPAR
-/- T-cells was negligible (Figure 24). In the Bcl-2 family, the 
disequilibrium of pro-apoptotic and pro-survival proteins leads to the 
translocation of pro-apoptotic proteins, such as Bim, to the mitochondria, 
causing cytochrome c release, caspase 3 activation, and subsequent apoptosis 
induction. 
 
 
 
Figure 24: Bim mRNA and protein expression in WT and Tc-PPAR
-/- mice. Mice were sacrificed 
after 24  h following cecum ligation and puncture (CLP) or sham surgery. (A) Bim mRNA 
expression detected in T-cells of WT and Tc-PPAR
-/- mice after CLP with real-time PCR. 
Graphs show mean values ± SD. 
*p<0.05. (B) Western analysis of Bim in WT vs. Tc-PPAR
-/-. 
 
Previously IL-2 receptor stimulation was shown to activate the PI3K/Akt 
pathway (110). In line, in my experiments using the IL-2 neutralizing antibody, 
less IL-2 receptors stimulation should reduce PI3K/Akt signaling and provoke 
higher Bim expression. As hypothesized, neutralizing IL-2 in Tc-PPAR
-/- 
increased Bim mRNA as well as protein expression after CLP (Figure 25). RESULTS     62 
 
 
 
Figure 25: Bim expression on mRNA and protein level in anti-IL-2 and IgG-treated Tc-PPAR
-/- 
mice. Mice received either 500 µg anti-IL-2 or 500 µg IgG at 1 h after CLP. Tc-PPAR
-/- sham 
mice were used as controls. (A) Fold Bim expression at mRNA level compared to sham control 
and (B) protein expression in T-cells following anti-IL-2 treatment. Graphs show mean values 
± SD. 
*p<0.05. 
 
This result proposes that the IL-2 receptor mediated modification of the PI3K 
pathway might be of high importance and that the regulation via PTEN is only 
secondary. To analyze this proposal further studies need to be performed which 
are outlined in the outlook of this thesis. 
5.5.  Therapeutical use of PPAR the antagonist GW9662 
To assess the therapeutic potential of PPAR inhibition, I administered the 
specific antagonist GW9662 to septic WT mice. Mice were treated with a 
concentration of 1 mg/kg GW9662 (111-112) to irreversibly inhibit PPAR for up 
to 24 h. To determine the optimal timing regime, mice were treated after 1, 3 or 
5 h following CLP (Figure 26A). This experimental setup is depicted in Figure 
26A. Herein, the hypothetical PPAR expression pattern (green line) is plotted 
in correlation to the T-cell count (red dotted line). Along this setup, 
administrating the antagonist too early, such as already 1 h after CLP might not 
be beneficial as PPAR is not expressed in naïve, unstimulated T-cells (95). In 
contrast, administered too late (5 h after CLP), T-cell depletion might have 
already proceeded excessively. In preliminary studies the most prominent T-cell 
depletion was observed at 24 h after CLP (97). At this particular time point, the 
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Examining the results of treating mice with 1 mg/kg GW9662 at 1, 3, or 5 h 
following CLP, I discovered CD3
+ T-cell counts in spleens of 160±42 cells/µg, 
238±20 cells/µg or 130±25 cells/µg, respectively. Highest T-cell counts were 
accomplished upon treatment at 3 h after CLP. Treatment at 1 and 5 h post-
CLP lowered T-cell counts to below DMSO-control levels (Figure 26B). 
 
 
 
Figure 26: Correlation of T-cell count and T-cell PPAR expression upon CLP and impact of 
GW9662 timing regime on T-cell count. (A) Hypothetical 24 h time-course of PPAR expression 
in T-cells (green line) and T-cell count (red dashed line) during mouse polymicrobial sepsis. (B) 
WT mice were treated with 1 mg/kg GW9662 at 1, 3, or 5 h or with 50 µl DMSO (10%) at 3 h or 
left untreated as controls. Absolute T-cell numbers in spleens and blood of WT mice after 
different treatments were analyzed by FACS analysis. Splenocytes were stained with anti-CD3ε 
and co-stained using anti-CD45 and Nuclear ORANGE to detect living lymphocytes. Graphs 
show mean values ± SD. 
**p<0.01. 
 
5.5.1. Absolute  T-cell  count 
T-cells and subpopulations were further quantified in the group treated with 
GW9662 at 3 h post-CLP. Herein, I observed significantly higher absolute T-
cells counts for CD3
+ T-cells mirroring increased CD4
+ and CD8
+ 
subpopulations in spleen and blood compared to solvent (DMSO) control 
groups (Figure 27). In blood, T-cell populations even increased above sham 
levels, proposing proliferation, possibly due to higher IL-2 expression and 
increased emigration from lymphoid organs (Figure 27B). 
 RESULTS     64 
 
 
Figure 27: Absolute T-cell count in spleens and blood of WT mice treated with 1 mg/kg GW9662 
at 3 h after CLP. WT mice were treated with 1 mg/kg GW9662 at 3 h or with 50 µl DMSO (10%) 
at 3 h or left untreated as controls. (A) T-cell quantification in spleen and (B) blood. Cells were 
stained with anti-CD3ε, anti-CD4, as well as anti-CD8a and co-stained using anti-CD45 and 
Nuclear ORANGE to detect living lymphocytes. Graphs show mean values ±  SD. 
*p<0.05; 
**p<0.01. 
 
To prove efficiency of 1  mg/kg GW9662 on T-cells at 24  h following CLP, I 
conducted an in vivo reporter assay. For this purpose, T-cells from GFP
+/+ mice 
were isolated and transduced with a lentivector expressing a fluorescent protein 
(mRuby) upon PPRE activation. By their green fluorescence, transduced GFP
+/+ 
T-cells can later easily be detected. Upon activation and binding of PPAR to 
PPRE in GFP
+/+ T-cells, mRuby is expressed and can be visualized by flow 
cytometry. During sepsis, PPAR expression promotes PPRE reporter activity.  
Figure 28A shows evaluation of PPRE reporter expression versus the T-cell 
count in GFP
+/+ T-cells depicted as FACS histogram. Reporter activity is 
increased upon CLP stimulation (green line) compared to sham control (blue 
line). When GW9662 is administered, the PPRE reporter activity is decreased 
(red line). Although the reporter construct is not specific for PPAR and 
activated upon PPAR or PPAR agonism as well, I was able to show that 
PPAR-specific inhibition with the antagonist GW9662 significantly decreases 
reporter activation. The quantification of these experiments confirmed this result 
(Figure 28B). Therefore, when treated with 1 mg/kg GW9662, mice showed a 
significantly lower PPRE reporter activity in their T-cells compared to untreated 
or DMSO-treated controls thus, proving effectiveness of the inhibitory potential 
of GW9662 on PPAR in T-cells for up to 24 h following CLP surgery. 
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Figure 28: In vivo PPRE reporter activity in response to GW9662 stimulation in septic mice. 
Primary T-cells from GFP
+/+ mice (blood and spleen) were transduced with an mRuby 
expressing PPRE reporter construct. Subsequently, transduced GFP
+/+ cells were injected into 
WT mice. 36 h later, CLP was performed and mice were treated with or without 1  mg/kg 
GW9662 at 3 h after CLP. Sham operated mice were analyzed as controls. (A) Flow cytometric 
histogram as representative of four experiments performed and (B) bar graph resembling 
quantification of reporter activity in GFP
+/+ cells. Graphs show mean values ± SD. 
*p<0.05. 
 
5.5.2.  Detection of T-cell apoptosis 
An abrogated T-cell depletion has shown to correlate with less apoptosis of 
splenic T-cells in Tc-PPAR
-/- mice, as well as in IgG-treated mice compared to 
WT or anti-IL-2 treatment. In line, I provide evidence for increased apoptosis 
when mice were injected i.p. with DMSO (10%). In contrast, GW9662 
application reduced apoptosis in WT mice when given at 3 h post CLP, as 
visualized by TUNEL assay and active caspase 3 staining (Figure 29). 
 
 
 
Figure 29: Detection of apoptosis via TUNEL assay and active caspase 3 staining upon 
GW9662 stimulation. (A) Quantification of apoptotic T-cells in spleens using anti-CD3ε and 
TUNEL assay. Values are expressed as mean percentage ± SD of apoptotic T-cells of total T-RESULTS     66 
cell amount in spleens. (B) Histological analysis of CLP-induced splenocyte apoptosis. Spleen 
sections were stained for active caspase 3 (brown) and counterstained with H&E. Dashed line 
surrounds T-cell-enriched white pulp (WP). RP, red pulp. Scale bars=100 µm. 
*p<0.05. 
 
Whether antagonism of PPAR  with GW9662 also affects survival similar to 
genetic depletion of PPAR was assessed by survival studies performed for 7 
days. GW9662 treatment significantly improved the survival rate to 75% at 7 d 
after CLP, compared to 8% survival in the solvent control group (Figure 30). 
This proved to be a statistical significant survival advantage at this time point. 
The survival rate upon PPAR antagonism with GW9662 was even higher 
compared to survival of Tc-PPAR
-/- mice, proposing an additional effect of 
GW9662 on other cells besides T-cells. This aspect will be further addressed in 
the discussion. 
 
 
 
 
 
Figure 30: Comparison of survival of GW9662-treated and DMSO-treated WT mice. Mice 
received either 1 mg/kg GW9662 or 50 µl DMSO (10%) at 3 h after CLP. Survival of mice was 
observed for 7d. 
**p<0.01. 
 
If increased survival and higher T-cell counts again correlate to less bacterial 
load and less end organ damage, GW9662 treatment should reduce CFUs in 
the peritoneum and reduce organ damage markers in the serum of mice 
subjected to CLP. As seen in Figure 31A, results for bacterial load point to less 
bacteria, gram-positive as well as gram-negative, in the peritoneum of mice with 
GW9662 treamtent compared to DMSO-treated mice. Furthermore, end organ RESULTS     67 
damage markers AST, ALT, and LDH were significantly less abundant upon 
GW9662 treatment compared to the solvent control group (Figure 31B). 
 
 
 
Figure 31: Bacterial clearance and end organ damage quantification in GW9662-treated mice. 
WT mice were subjected to CLP and treated with 1 mg/kg GW9662 or DMSO (10%) after 3h. 
(A) Bacterial load presented as colony forming units (CFU) of gram-positive or gram-negative 
bacteria in 100 µl of peritoneal lavage fluid. (B) Serum activities of lactate dehydrogenase 
(LDH), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in serum. 
*p<0.05. 
 
5.5.3. PPAR-dependent apoptotic signaling during sepsis after 
GW9662 
To verify whether the previously identified molecular mechanisms of PPAR-
dependent apoptosis were counteracted by GW9662, I investigated protein and 
mRNA expression of the previously discussed targets. Two possible apoptosis 
pathways were identified in the previous experiments in Tc-PPAR
-/- mice. The 
first one is based on increased IL-2 expression and downstream pro-survival 
signaling when PPAR is genetically ablated. Upon PPAR antagonism with 
GW9662, IL-2 as well as Bcl-2 mRNA expressions were significantly increased. 
In addition, I identified PPAR to provoke PTEN expression in WT mice 
counteracting pro-survival PI3K/Akt signaling with increased Bim expression. 
GW9662 promotes, similar to Tc-PPAR
-/-, reduced PTEN and subsequent 
lower Bim expression in WT T-cells (Figure 32). 
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Figure 32: Pro- and anti-apoptotic signaling on mRNA level in WT mice treated with GW9662 or 
DMSO. WT mice were treated with either 1 mg/kg GW9662 at 3 h, with 50 µl DMSO at 3 h or 
left untreated subsequent to CLP. Mice were sacrificed 24 h following CLP or sham surgery. 
Spleens were dissected and T-cells were isolated. X-fold mRNA expression of anti-apoptotic IL-
2 and Bcl-2, as well as pro-apoptotic Bim and PTEN in T-cells compared to sham control levels 
detected by real-time PCR. Data are means ± SD. 
*p<0.05; 
**p<0.01. 
 
Higher mRNA expression levels also provoked increased protein expression of 
Bcl-2 and Bim in septic GW9662-treated T-cells compared to WT T-cells (Figure 
33A). This coincided with enhanced Akt phosphorylation (Figure 33A), which 
can be taken as an indicator for decreased PTEN activity. Similar to genetic 
ablation of PPAR, GW9662 enhanced NFAT binding to its responsive element 
in the IL-2 promoter thus, provoking increased IL-2 mRNA (Figure 33B). 
Enhanced NFAT binding correlated with increased intracellular IL-2 levels 
(Figure 33C). 
 
 
 
Figure 33: Analysis of apoptosis pathways upon GW9662 or DMSO treatment. WT mice were 
treated with either 1 mg/kg GW9662 at 3 h, with 50 µl DMSO at 3 h or left untreated subsequent 
to CLP. Mice were sacrificed 24 h following CLP or sham surgery. Spleens were dissected and 
T-cells were isolated. (A) Western analysis of Bcl-2, Bim, and phosphorylated Akt (pAkt) in T-
cells. (B) Association of NFAT with its response element within the IL-2 promoter analyzed by 
ChIP analysis. (C) Intracellular IL-2 protein amount in T-cells. Cell populations shown are gated RESULTS     69 
on living, CD45
+, CD3ε
+ cells and percentage numbers indicate IL-2-expressing T-cells. Data 
are means ± SD. 
**p<0.01. 
 
5.5.4.  Exploring the therapeutic window of GW9662 medication 
As announced previously, the dosing of 1 mg/kg GW9662 did not improve T-cell 
depletion after 5 h following CLP. Therefore, I questioned whether higher dosing 
(3 mg/kg) applied 5 h after CLP might improve T-cell counts and possibly also 
survival. This experimental setup abrogated CD3
+ T-cell depletion. Investigating 
T-cell subpopulations, I recognized that CD4
+ T-cell counts were decreased, 
whereas the amount of CD8
+ T-cells was increased (Figure 34). 
 
 
 
Figure 34: Absolute T-cell count in WT mice treated with 3 mg/kg GW9662 or DMSO at 5 h after 
CLP. (A) T-cell quantification in spleens and blood of untreated WT mice, with 3 mg/kg GW9662 
or with DMSO treatment at 5 h after CLP. Cells were stained with anti-CD3ε, anti-CD4, as well 
as anti-CD8a and co-stained using anti-CD45 and Nuclear ORANGE to detect living 
lymphocytes. Data are means ± SD. 
*p<0.05. N.S., not significant. 
 
 
So far, an abrogation of all T-cell populations accounted for increased survival. 
However, the resulting subpopulation-devided T-cell counts upon treatment with 
3 mg/kg GW9662 at 5 h after CLP are very heterogeneous thus no survival rate 
can be predicted. When performing survival studies for 7 days with this 
experimental setup I will be able to identifiy which T-cell type is essential for 
survival. Considering this treatment regime results in a significantly better 
survival compared to controls, the depletion of CD4
+ cells is unimportant and 
surviving CD8
+ T-cells are responsible for pro-survival effects. On the contrary, 
if mice do not show improved survival with low CD4
+ cell counts and high CD8
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counts, the depleted CD4
+ T-cell population would have been important for 
survival. 
The result of this experiment demonstrates that animals treated at 5 h post CLP 
with 3  mg/kg GW9662 had only minor, at 7 days pot-CLP not statistically 
significant survival advantages of 42% vs. 8% (Figure 35). Thus, my experiment 
indicates that CD4
+ T-cells contribute to sepsis-related immunodeficiency and 
thereby reduce survival of the septic host. 
 
 
 
Figure 35: Comparison of survival of GW9662-treated and DMSO-treated Tc-PPAR
-/- mice. 
Mice received either 3 mg/kg GW9662 or DMSO (10%) at 5 h after CLP. Survival of mice was 
observed for 7d. N.S., not significant. 
 
In summary, pharmacological antagonism of PPAR with 1  mg/kg GW9662 
given at 3  h after CLP abrogated T-cell depletion and significantly improved 
survival of WT mice. At a concentration of 3 mg/kg applicated at 5 h after CLP, 
GW9662 failed to improve survival, probably due to decreased CD4
+ T-cell 
numbers. 
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6. DISCUSSION 
The present thesis proposes inhibition of PPAR as a potential target to achieve 
protection against the deleterious consequences of T-cell death during sepsis. 
In the following, the underlying investigation will be discussed and analyzed in a 
context of problems and findings of current sepsis therapy. Furthermore, the 
role of T-cell depletion during sepsis, the identified apoptosis pathways, 
systemic effects of GW9662 application, and the use of the different sepsis 
models are surveyed. Finally, the consequences of my findings for current 
sepsis treatment will be discussed. 
 
6.1.  Problems in current sepsis therapy 
Septic patients represent an inhomogenous group, since the individual’s 
immune response can be modulated by a variety of factors, such as the nature 
of the infectious stimuli, the host genetic makeup (i.e. predisposition to 
inflammation), comorbidities, and exogenous factors (e.g. medication, blood 
transfusion, etc.). This heterogenity makes it difficult for physicians and 
scientists to design effective therapies. Some patients may need suppression of 
the first inflammatory response, but most of the patients survive this initial attack 
of sepsis, and may need therapies that improve their immune system and 
restore their ability to fight the infection. Despite the development of novel 
therapeutic entities, eradication of the septic focus, early administration of 
antibiotics and stabilization of cardiovascular functionality still remains the most 
effective causal and supportive therapy to treat patients with severe sepsis or 
septic shock (113). Marginal improvements in survival have recently been 
observed using adjunctive approaches such as extracorporal removal of 
endotoxins (114) or early therapy with activated protein C (115). 
The therapeutical treatment regime using PPAR antagonists proposed in this 
thesis might represent a novel approach, targeting the deleterious 
consequences of the second, hypo-inflammatory phase. Thereby, in contrast to DISCUSSION     72 
previous investigations, a rescue therapy might be developed that could be 
applied after the onset of sepsis. Therapies targeting the first, hyper-
inflammatory phase on the contrary, have to be given in advance to sepsis, 
which is mostly difficult to predict. 
 
6.2.  T-cell apoptosis during sepsis 
During sepsis, the immune response is characterized by changes in circulating 
lymphocytes. For a long time, it was unclear whether the decrease in the 
number of lymphocytes in septic patients is due to apoptosis, recruitment from 
the circulation to the peripheral tissues, changes due to transfusion of blood 
products, or hemodilution from large crystalloid infusions. Based upon published 
literature (77, 116-117) and my own data, we proved that the decrease is 
largely due to apoptosis. Decreases in lymphocyte numbers are thought to 
contribute to the immunosuppression observed during sepsis and increased 
susceptibility to infections (118). In my experiments, the control groups (WT 
mice and DMSO-treated mice), without genetical or pharmacological PPAR 
depletion, exhibited a high T-cell apoptosis, which was accompanied by a low 
survival rate. When inhibiting this deleterious T-cell apoptosis by genetical or 
pharmacological antagonism of PPAR, mouse survival was increased. 
Currently, the thought is that apoptotic cell death and handling of apoptotic cells 
by the innate immune system provides a mechanism whereby self-tolerance is 
maintained by deletion or active immune regulation. Further, exposure of the 
immune system to a large number of apoptotic cells can induce suppression of 
immunity. Along with eliciting a compromised immune state, T-cell apoptosis 
might also induce alterations in other immune cells. Previous publications 
revealed that uptake of apoptotic cells by phagocytes promotes an 
immunosuppressive environment that induces anergy and avoids inflammatory 
responses to pathogens (119). The presence of apoptotic cells during 
macrophage activation has been shown to increase their secretion of IL-10 and 
TGF (M2 phenotype) while decreasing the secretion of TNF, IL-1 and IL-12 
(M1 phenotype) (120-121). This shift of pro- to anti-inflammatory cytokines in DISCUSSION     73 
response to pathogen contact further impairs the host’s response to infection. 
Transfer of apoptotic splenocytes to animals undergoing CLP resulted in 
decreased survival compared to untreated animals. Interestingly, in the same 
studies, transfer of necrotic cells was associated with higher levels of IFN 
production by splenocytes and improved survival following CLP (122). 
Therefore, apoptotic cells and their phagocytosis further promote an 
immuneparalysed state and reduce the clearance of invading pathogens. 
Furthermore, suppression is induced by the induction of immune deviation (e.g. 
Th1-Th2 shift) and the activation of CD8
+ T regs (123). Therefore, reduced 
apoptosis might cause an immune stimulation, enhance antimicrobial defenses 
and limit organ damage. 
In my experiments, I discovered CD4
+ cells to be necessary for survival of 
sepsis. When GW9662 was applied at 5 h after CLP, CD8
+ but not CD4
+ cells 
survived. This CD4
+ cell-depleted state resulted in a survival rate, which was 
similar to survival of control mice. This special role of CD4
+ cells has also been 
discussed in literature previously. Martignoni et al. proposed that CD4
+ T-cells 
are unexpectedly active in the initial immune response to polymicrobial sepsis 
such that they promote early bacterial clearance, possibly by influencing 
neutrophils in an IFN-dependent manner. A lack of CD4
+ cells is associated 
with increased IL-6 concentrations, increased bacteremia, and decreased 
neutrophil activity. Surprisingly, the lack of CD4
+ cells altered survival within the 
first 30 h of sepsis. Traditionally, T-cells contribute to an effective defense 
against extracellular bacteria during infections after 48 to 96 h. However, there 
is emerging evidence that lymphocytes play an early role during acute injuries. 
This implicates memory CD4
+ T-cells, which can respond to antigens within an 
acute time frame to be of high importance. In my experiments inducing sepsis, I 
used the CLP sepsis model. In the CLP model the bacteria released are 
endogenous and originate from the gut. Herein, it is likely that peritoneal 
memory CD4
+ cells may be antigenic toward the bacteria released by CLP. If 
this is the case it is probable they are of a Th1 phenotype. Memory Th1 cells 
can rapidly secrete IFN upon recognition of the processed bacterial antigen. 
IFN has been reported to activate phagocytes and increase the ability to clear DISCUSSION     74 
bacteria (124). During the first 18 h of sepsis, T-cells in the mouse peritoneum 
secrete IFN or mediators that increase neutrophil IFN production (118). 
Recently Lawrence et al. investigated the question why especially CD4
+ T-cells 
are dying. They proposed that a lower CD4
+ ATP content is associated with 
apoptosis and worses the clinical outcome of sepsis. They speculate that this 
lower CD4
+ ATP content may be due to mitochondrial dysfunction, or to anergy 
of the lymphocytes to mitogen stimulation. Or it may simply represent another 
form of organ dysfunction, described as lymphocyte bioenergetic failure in the 
setting of sepsis (125). 
 
6.3.  Apoptosis pathways during sepsis modified by PPAR 
I refer to two pro-apoptotic pathways that are highly active during sepsis and 
are induced upon PPAR activation in vivo. The first one proposes limited pro-
survival IL-2 signaling during sepsis in activated T-cells. IL-2 is known to 
activate pathways that lead to proliferation, survival and cytokine production of 
effector T-cells. IL-2 expression is controlled almost entirely at the 
transcriptional level. The IL-2 promoter region contains defined binding sites for 
many inducible transcription factors, such as NFAT, NFB, AP-1, and CREB 
(94). PPAR has been shown to suppress IL-2 expression by ligating these 
important transcription factors (transrepression) (60, 126). 
The transcription factor NFAT is in large part responsible for IL-2 transcription. 
This protein is not the limiting factor for IL-2 starvation during sepsis, which can 
be explained by its regulation. NFAT is regulated by Ca
2+ and the 
Ca
2+/calmodulin-dependent serine phosphatase calcineurin. NFAT protein is 
phosphorylated and resides in the cytoplasm in resting cells. Upon stimulation, 
it is dephosphorylated by calcineurin, translocates into the nucleus, and 
becomes transcriptionally active, thus providing a direct link between 
intracellular Ca
2+ signaling and gene expression. In activated cells, such as in 
septic T-cells, it was shown that calcineurin is present in the nucleus of 
stimulated cells, where it maintains the dephosphorylated status and nuclear 
localization of NFAT. When Ca
2+ entry is prevented or calcineurin activity is DISCUSSION     75 
inhibited, NFAT is rephosphorylated by NFAT kinases and rapidly leaves the 
nucleus, and NFAT-dependent gene expression of IL-2 is terminated (127). 
During sepsis, NFAT is located in the nucleus and is there bound to PPAR and 
thus not able to promote transcription of IL-2. 
IL-2 withdrawal provokes activation of the intrinsic, mitochondrial apoptosis 
pathway. This so called cytokine withdrawal apoptosis dramatically reduces the 
expanded T-effector population and is principally regulated by pro- and anti-
apoptotic members of the Bcl-2 family. In healthy organisms on the contrary, 
autocrine IL-2-receptor stimulation initiates intracellular anti-apoptotic signaling 
pathways, including anti-apoptotic Bcl-2 expression. Tc-PPAR
-/- T-cells are 
protected from apoptosis due to high IL-2 expression levels. These 
observations were corroborated by my experiments neutralizing IL-2 during 
peritonitis, which in turn provoked T-cell apoptosis and impaired septic 
outcome. 
Previous reports showed that over-expression of the IL-2-receptor downstream 
target Bcl-2 improves T-cell survival (80). In 2009 Weber et al. performed a 
study with patients with early stage severe sepsis, unravelling their expression 
profile for pro- and anti-apoptotic members of the Bcl-2 family of proteins. They 
found a similar expression pattern compared to the results described in my 
thesis. Gene expression of pro-apoptotic Bcl-2 family members Bim, Bad and 
Bak were induced and a downregulation of the anti-apoptotic Bcl-2 and Bcl-xl 
proteins was observed in peripheral blood. They also proposed that this 
constellation affects cellular susceptibility to apoptosis and complex immune 
dysfunction in sepsis, however, they did not advise a possible target to limit 
these effects, as it is anticipated in this work by PPAR (128). 
In line with these observations, my work provides evidence for Bcl-2 
upregulation on mRNA and protein level. Bcl-2 functions to suppress apoptosis 
in a variety of cell systems. It is localized in the endoplasmatic reticulum, 
nuclear envelope, and outer mitochondrial membranes. Several mechanisms 
have been proposed to explain the anti-apoptotic function of Bcl-2. It acts as a 
regulator of Ca
2+ homeostasis or as an antioxidant. Bcl-2 forms heterodimers 
with the pro-apoptotic protein Bax and might thereby neutralize its death 
effector properties. Bcl-2 prevents the release of potent mitochondrial activators DISCUSSION     76 
of caspases. The association of Bcl-2 with the mitochondrial apoptosis-
activating factor Apaf1 and the blockade of cytochrome c release may inhibit the 
activation of caspase 9 and 3. Bcl-2 also acts by modulating collapse of the 
mitochondrial transmembrane potential that occurs during apoptosis (129). 
Further, Bcl-2 protects against apoptosis by binding to and neutralizing pro-
apoptotic Bcl-2 family members such as Bim, Puma, and Noxa (88). It can 
prevent apoptotic cell death from a wide array of adverse stimuli, including 
hypoxia, serum and growth factor withdrawal, glucocorticoids, and ionizing 
irradiation, among others (28). In Figure 36 the proposed pro-apoptotic 
pathway, described by activated PPAR ligating NFAT, IL-2 withdrawal and 
reduced Bcl-2 expression is summarized.  
 
 
 
Figure 36: PPAR binding to NFAT reduces pro-survival IL-2 transcription. Ligand-activated 
PPAR transrepresses NFAT by direct ligation thus, preventing NFAT-dependent IL-2 
transcription. Pro-survival autocrine IL-2 signaling via the IL-2 receptor (IL-2R) is reduced and 
subsequently pro-survival Bcl-2 expression is repressed. PPAR antagonism with GW9662 
promotes IL-2 expression and pro-survival Bcl-2 signaling. 
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The PI3K pathway is one of the major signaling pathways activated upon TCR, 
IL-2 receptor, and CD28 stimulation, leading to T-cell activation, proliferation, 
and cell survival. Activation of the pathway is negatively regulated by PTEN, a 
phosphatidylinositol-phosphatase that is transcriptionally regulated by PPAR. 
Several mouse models deficient for the molecules involved in PI3K signaling 
suggest that impairment of PI3K downstream signals leads to dysregulation of 
immune responses, and in some cases, autoimmunity (110, 130). 
PTEN was originally identified as a tumor suppressor because of its high 
frequency mutations in various types of tumors. PTEN is regulated on 
transcriptional level, i.e. by PPAR, as well as on posttranslational level by 
phosphorylation. The pro-apoptotic property of PTEN is mainly dependent on its 
lipid phosphatase activity, which antagonizes the PI3K pathway and inhibits cell 
survival. PTEN dephosphorylates PIP3 to phosphatidylinositol-diphosphate 
(PIP2), and consequently reduces Akt phosphorylation (131). Phosphorylated 
Akt promotes cell survival by phosphorylating its substrates, including the 
Forkhead transcription factor 3a (FOXO3a). While FOXO3a is phosphorylated 
by Akt, it will be retained in the cytoplasm. However, is Akt not phosphorylating 
FOXO3a, during e.g PTEN-dependent inhibition of the PI3K-pathway, 
dephosphorylated FOXO3a translocates to the nucleus and induces target gene 
expression, i.e. for the pro-apoptotic proteins Bim and Fas ligand. Upregulation 
of Bim in turn promotes cytochrome c release from the mitochondria and 
caspase-dependent apoptosis (131). Expression of PTEN in activated CD4
+ T-
cells inhibits IL-2-dependent proliferation, confirming PTEN as a negative 
regulator of IL-2 receptor signaling (132). By its effect on PTEN, PPAR might 
therefore induce the pro-apoptotic target gene Bim and induce T-cell depletion. 
 
How Bim promotes apoptosis has been the subject of some debate. Bim has 
been first shown to interact with pro-survival Bcl-2 which has been suggested to 
be the key ability of Bim to induce apoptosis. However, alternatively it was 
shown that Bim can bind directly to the pro-apoptotic Bax and Bak proteins to 
initiate apoptosis. A recent study finally puts this debate to rest and proved Bim 
to interact with pro-survival Bcl-2, thereby releasing Bax or Bak proteins to 
promote apoptosis (133). Bim is the most extensively studied pro-apoptotic   DISCUSSION     78 
Bcl-2 family member and is required for cell death subsequent to cytokine 
withdrawal, death of autoreactive T-cells and for termination of acute T-cell 
responses in viral infections. In 2008, the group of Hotchkiss and colleages 
showed that Bim knockout mice have nearly complete protection against 
sepsis-induced lymphocyte apoptosis. They confirmed these experiments by 
using Bim siRNA which also protected lymphocyte apoptosis and exhibited a 
better survival of septic mice (88). Bim activation and apoptosis induction in T-
cells is considered as one of the most critical pathogenic mechanisms in sepsis 
(88, 108-109). 
In this regard, Williams et al. also suggested that stimulation of the PI3K 
pathway may be an effective approach for preventing or treating sepsis and/or 
septic shock (134). In an experimental model of sepsis, this pathway was 
further confirmed showing that overexpression of pAkt in lymphocytes 
decreased lymphocyte apoptosis and improved survival during sepsis (135). In 
my work, I found PPAR-dependent PTEN expression to reduce 
phosphorylation of Akt and to induce Bim expression thus, promoting apoptosis 
(Figure 37). 
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Figure 37: PPAR-induced PTEN expression promotes pro-apoptotic signaling. Ligand-
dependent activation of PPAR promotes PTEN expression thus, reversing the phosphoinositol-
3 kinase (PI3K) dependent phasphatidylinositol-diphosphate (PIP2) to phosphatidylinositol-
triphosphate (PIP3) phosphorylation. Akt remains in its unphosphorylated state and promotes 
Bim expression. If GW9662 is applied, PTEN expression is ablated, PI3K signaling is 
maintained and phosphorylated Akt (pAkt) prevents pro-apoptotic Bim expression. 
 
Hoogerwerf et al. performed a gene profiling of apoptosis regulators in highly 
purified monocytes, granulocytes and CD4
+ T-cells. Anti-apoptotic profiles were 
found in monocytes and granulocytes, while CD4
+ T-cells displayed a foremost 
pro-apoptotic mRNA profile. In detail, CD4
+ T-cells presented increased 
expression of Bim, PMAIP1 and BNIP3L in addition to an increased Bax mRNA 
expression. Furthermore, they discovered no signs of activation of the death 
receptor pathway, since no alterations were found in death receptor TNFRSF21 
expression. Moreover, cFLIP, an inhibitor of death receptor signaling, appeared 
to be upregulated in CD4
+ lymphocytes (136). However, sepsis is an extremely 
complex disorder involving activation of numerous intersecting cascades, 
including pro-inflammatory, anti-inflammatory, coagulation and complement 
system (76). Thus, it is not surprising that multiple pathways of cell death may 
be involved in sepsis. Furthermore, different bacteria, such as released by CLP, 
possess different toxins that may activate unique cell death programs. 
 
6.4.  Sytemic effects of PPAR antagonism with GW9662 
GW9662 irreversibly inhibits PPAR with minor effects on other PPARs (45). To 
verify GW9662 as therapeutic drug to improve sepsis therapy, its action not only 
on T-cells needs to be clarified. PPAR expression patterns during sepsis and 
possible consequences of inhibition of PPAR with GW9662 must be taken into 
consideration. 
PPAR is differentially expressed and exerts diverse action on immune cells 
during sepsis. In macrophages, PPAR has been shown to favor an anti-
inflammatory phenotype (M2 phenotype) (38), which is characterized by 
attenuated production of pro-inflammatory mediators, but enhanced secretion of 
anti-inflammatory ones, such as IL-10, TGFβ, and PGE2. This limits defense DISCUSSION     80 
against pathogens thus, when PPAR is inhibited by GW9662, a pro-
inflammatory M1 phenotype might be favored and stimulates macrophages to 
secrete cytokines and improve pathogen clearance. However, it was recently 
shown that LPS treatment rapidly down-regulates PPAR in macrophages after 
6 to 15  h by miR-27b-dependent mRNA destabilization, followed by its up-
regulation again at later time points (67). Early after the onset of sepsis, I 
suggest that GW9662 does not exert significant effects on macrophages. 
By attenuating NF-B transactivation, PPAR inhibits cytokine expression of 
e.g. TNF or IL-12 (137), the expression of vascular cell adhesion molecule-1 
(VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) (138). Preventing this 
action with GW9662, more leukocytes are able to enter the site of infection and 
promote pathogen elimination. Moreover, the expression of the inducible pro-
inflammatory proteins, cyclooxygenase-2 (COX-2) (61), cytosolic phopholipase 
A2, and inducible nitric oxide synthase (iNOS) (139) are blocked (61, 139-141). 
An inhibition of this pro-inflammatory potential by GW9662 on the contrary 
might be rather harmful since reduced systemic pro-inflammatory effects might 
also reduce pathogen killing. In vivo studies showed that administration of the 
PPAR agonist 15-deoxy-
12,14-prostaglandin J2 (15d-PGJ2) prior to 
polymicrobial sepsis reduces lung injury and neutrophil trafficking to lung and 
small intestine (142). 15d-PGJ2 enhances PPAR functions in the lung, 
decreases NFB activity, and promotes expression of the cytoprotective heat 
shock protein 70 (HSP70) (143). In turn, the heat shock response is amplified 
and correlates well with improved lung injury. In this regard, GW9662 
application might again be rather harmful, expecting worse lung injury. Agonist 
treatment might be more effective in this respect, but difficult to handle, since 
PPAR agonists must be applicated before the onset of sepsis. 
The role of PPAR in T-cells and the effects of GW9662 treatment on T-cell 
apoptosis were elucidated in detail in this work. There are some additional 
PPAR-mediated effects on T-cells that were not taken into consideration in this 
work so far. PPAR can inhibit expression of several T-cell cytokines upon 
activation, including the classical Th1-cell cytokine IFN (144). Moreover, by 
reducing IL-12 production in dendritic cells, PPAR reduces IFN production by 
T-cells. This ability indicates that PPAR might play a role during differentiation DISCUSSION     81 
of naïve T-cells into their effector subsets, favoring the anti-inflammatory Th2 
cells. Conversely, it was shown that in the presence of IL-4, a cytokine 
important for the development of Th2 cells (145), monocytes can provide a 
potential PPAR-specific ligand through upregulation of the 12/15 lipoxygenase 
(146). 13-HODE is produced and can be taken up by T-cells to activate PPAR 
thus, further promoting a Th2 phenotype (146-147). These observations 
suggest that GW9662 stimulation reduces anti-inflammatory Th2 phenotype 
development and promotion of a pro-inflammatory Th1 phenotype that further 
activates M1 macrophages and indirectly boosts pathogen elimination. 
 
A critical issue of this work was to determine the best time point of therapeutic 
antagonism of PPAR with GW9662. Time kinetics revealed that administration 
of 1  mg/kg GW9662 3  h following CLP not only completely prevented T-cell 
depletion detected at 24 h post CLP, but increased T-cell counts to ~130% in 
blood. This effect might be achieved by increased IL-2 expression causing a 
limited apoptosis and an enhanced proliferation of T-cells. GW9662 
administered too early might have no beneficial effect due to low PPAR 
expression in T-cells at this time. Applying 3 mg/kg GW9662 at 5 h improved 
the CD3
+ cell count, but decreased CD4
+ cell numbers, which proved to be 
deleterious during sepsis, as this treatment regime resulted in low survival 
rates. Here, PPAR antagonism might not be advantageous, because T-cell 
depletion has already proceeded excessively. Therefore, GW9662 is particularly 
advantageous early after the onset of sepsis, when PPAR is highly expressed 
and T-cells have not yet depleted. 
Furthermore, markers that define the immunological status of the patient, and 
that gives information about a possible susceptibility for GW9662 treatment, are 
highly needed and would be of clinical benefit. 
 
6.5.  Systemic inflammation vs. sepsis - LPS vs. CLP 
Besides sepsis, also systemic inflammatory conditions provoke T-cell apoptosis 
and are often developed after i.e. extracorporal circulation as needed for 
cardiac bypass surgery (148). In my experiments I used LPS to induce systemic DISCUSSION     82 
inflammation. I demonstrated that Tc-PPAR
-/- mice exhibited significantly lower 
T-cell depletion compared to WT mice. Therefore, antagonizing PPAR 
following extracorporal circulation during cardiac surgery might be a promising 
option to improve immune responses in patients undergoing on-pump cardiac 
surgery. 
During my experiments I decided to change the animal model. There were 
several arguments that supported my decision: experimentation involving single 
organisms or even their products, such as LPS, is useful to characterize 
response patterns and treatments directed against one particular microbe. But 
models of endotoxemia are of doubtful relevance to clinical sepsis, which is 
commonly polymicrobial, providing gram-negative and –positive organisms, as 
well as aerobic and anaerobic bacteria. Typically, an infection that leads to 
sepsis begins as a focus of microbes that becomes systemic. Mostly pathogens 
do not originate from the periphery de novo. During sepsis, the microbes 
infecting the patient often originate from the persons own flora, finding their way 
into wounds, gut perforation, or microbial translocation from the gut (93). Thus, I 
chose to perform the CLP model. As one of the most widely used models of 
sepsis and septic shock, the CLP model satisfies many of the criteria listed for 
an appropriate model: it is polymicrobial, has focal infection origins, produces 
septicemia, and releases bacterial products into the periphery. And it has the 
advantage that the microbes are of mixed “host origin” rather than being 
exogenously introduced. Induced sepsis severity ranges from acute and fatal to 
chronic and enables a wide range of experimentation (93). 
Recent studies suggest immune dysfunction seen after the onset of 
polymicrobial sepsis, as produced by cecum ligation and puncture, is not 
caused by endotoxin alone, but may be caused by the combined effect of the 
necrotic tissue and other microbial components (149). 
 
6.6. Possible  consequences for sepsis treatment 
In my model, activation of PPAR contributes to the induction of apoptosis via 
two important pathways, namely IL-2 repression and PTEN induction. I 
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and thereby limit self-harmful effects for the host. On the other hand, this effect 
consequently impairs the host’s resistance to continuing infections and might 
cause or promote organ injury.  
Sepsis represents a race to the death of the pathogen and the host immune 
cells and the pathogens try to find an advantage by inducing death in billions of 
immune effector cells. The majority of deaths in sepsis occur in the 
immunosuppressed phase. Simple and rapid tests to identify the immune status 
of the patient (hyper- vs. hypoinflammatory phase) are needed to guide the 
immunologic therapy. In this thesis, I propose PPAR as therapeutic target to 
improve sepsis therapy, when applicated at the hyper-inflammatory phase to 
prevent the deleterious hypo-inflammatory state. Although I identified a rather 
narrow time frame for beneficial treatment of septic mice with GW9662, I still 
believe that the possibility of giving PPAR antagonists after the onset of sepsis 
represents a high rescue potential. This treatment regime is of special 
importance because it displays a method to treat septic patients after the onset 
of sepsis. Previous studies targeting the pro-inflammatory phase used inhibitors 
proposing a treatment before the onset of sepsis, which is often difficult to 
handle. Furthermore, in following experiments it needs to be investigated if a 
repeated application of antagonists or the application of reversible binding 
antagonists might broaden the therapeutic window. I do not believe that there is 
any possibility to improve sepsis pathophysiology with PPAR antagonists at 
earlier time points, because activation of the adaptive immune system is 
needed for high PPAR expression levels in T-cells. If the antagonist is given to 
early, no effect is seen at later time points either, probably due to interception of 
the antagonists by cells highly expressing PPAR at this time. GW9662 binds 
irreversible and is thus, not available for T-cells at later stages. 
I hypothesize that in order to save patients with severe sepsis and septic shock 
from the vicious circle of secondary infection, chronic multiple organ failure, and 
death, it will be of high importance to concentrate on the underlying immune 
pathophysiology in the hypoimmune phase (Figure 38). In the next steps, 
GW9662 treatment should be tested for its ability for widespread routine use. DISCUSSION     84 
Therefore, I suggest that my findings might open novel “therapeutic windows” in 
the treatment of sepsis by targeting two apoptosis pathways using only one 
blocking agent. 
 
 
 
Figure 38: Therapeutical timing regime for treatment with PPAR agonists and antagonists 
during the course of sepsis. Before or at the onset of sepsis, treatment with PPAR agonists is 
beneficial, blocking the hyperinflammatory phase. During the hyperinflammatory phase, 
application with PPAR antagonists improved survival. In the hyperinflammatory phase, neither 
PPAR agonism nor its antagonism would be advantageous in preventing organ dysfunction, 
secondary infections and eventually death. 
 
6.7. Outlook 
6.7.1.  The role of PTEN during sepsis progression 
In this thesis, I provide evidence for increased expression of PTEN upon PPAR 
activation in T-cells. If mice are treated with GW9662, PPAR activation is 
inhibited and PTEN expression is decreased. Using GW9662, the subsequent 
PI3K/Akt signaling pathway is not suppressed anymore and promotes pro-
survival signals. But the direct link between PTEN expression and the PI3K/Akt 
signaling is still missing. Possibly, inhibition of the PI3K/Akt pathway results DISCUSSION     85 
from diminished autocrine IL-2 receptor signaling. To analyze this alternative, a 
dominant negative PTEN construct, as well as a WT PTEN expressing 
construct will be lentivirally transduced into primary mouse T-cells. Transduced 
T-cells will be injected i.v. into WT mice and CLP will be performed. If my 
hypothesis of PTEN as crucial for apoptosis induction is true, cells 
overexpressing PTEN will have reduced pro-survival PI3K/Akt signaling and die 
by apoptosis. In contrast, T-cells carrying the dominant negative mutant of 
PTEN will have no reduction in PI3K/Akt pathway. This experimental setup 
should clarify the question whether the tumor suppressor PTEN, regulated by 
PPAR, plays an important role during sepsis-induced T-cell depletion. PTEN 
might then represent another target, besides PPAR, to reduce T-cell apoptosis 
and to improve the immune suppressed status of septic patients. 
 
6.7.2.  Impact of GW9662 on T-cells from septic patients 
In my experiments I proved efficacy of the specific PPAR antagonist GW9662 
in an animal model of sepsis. However, it remains unclear whether GW9662 
promotes the same effects in human T-cells. Therefore, I propose that T-cells 
from septic patients should be isolated and treated with GW9662. In previous 
experiments with T-cells from septic patients, stimulation with PPAR agonists, 
such as rosiglitazone, resulted in apoptosis. Further, PPAR ligands were 
identified in serum of patients blood (89), suggesting active PPAR to promote 
apoptosis of T-cells during sepsis in humans. To confirm my hypothesis of 
PPAR-induced T-cell apoptosis during sepsis, primary human T-cells from 
septic patient blood should be analyzed for apoptosis induction and PPAR 
activation upon GW9662 treatment. Furthermore, it is still questionable whether 
primary human T-cells react similar in concerns of apoptosis induction, cytokine 
regulation, and Bcl-2 family member expression when treated with the PPAR 
antagonist. If these experiments mirror the results of the underlying work, sepsis 
therapy with GW9662 (or a comparable PPAR antagonist) is getting one step 
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6.7.3. Antagonism of S1P to improve peripheral T-cell counts 
during sepsis 
In my experiments I detected apoptosis of splenic T-cells. This led to reduced 
peripheral T-cell counts and impaired resistance against pathogens. Another 
organ where apoptosis of T-cells occurs and which might be another target to 
improve peripheral T-cell availability and subsequently improve survival might 
be the thymus. The thymus is the main provider for naïve T-cells during life. It 
decreases in size and functionality throughout the lifespan. This phenomenon is 
called thymus involution. For a long time it has been assumed that the thymic 
function gradually decreases after puberty. By the age of 18, the periphery was 
thought to be filled with a complete repertoire of antigen-reactive T-cells. In 
recent years, more and more data have contradicted this dogmatic view and 
provided demonstrative evidence that the adult thymus remains active late in 
life and still generates functional T-cells for the peripheral lymphoid repertoire 
(150-151). During acute inflammatory conditions such as sepsis, a similar 
pattern of thymus involution can be recognized. In contrast to age-dependent 
thymus involution, this acute modification is transient, reversible and followed by 
a phase of hyperproliferation of the thymus. It is called acute thymus involution 
(152). In addition to the so far identified T-cell apoptosis in the blood and spleen 
of septic patients, this mechanism adds dramatically to the immunosuppression 
and subsequent bad outcome of sepsis. Very recently, acute thymus involution 
has attracted attention for another disease that is accompanied by a massive  
T-cell depletion, the infection with the HI-virus. HIV infection leads primarily to 
an infection and subsequent depletion of CD4
+ T-cells. Similar to sepsis, HIV 
infected patients suffer from immunosuppression and are likely dying by 
secondary diseases. For HIV infection, it was recently shown that inhibition of 
the underlying thymus involution reduces the viral load and increases the 
amount of viable T-cells in the periphery (153). In line with this finding, the 
underlying mechanism for sepsis-related T-cell depletion should be clarified. 
The main emigration factor for naïve T-cells is the lipid sphingosine-1-
phosphate (S1P). T-cells follow a S1P gradient out of the thymus in the lymph 
and blood (upper part of Figure 39) (154-155). S1P is usually secreted by DISCUSSION     87 
thrombocytes and erythrocytes, but recent findings also proposed S1P release 
from apoptotic cells (156-157). During sepsis, there is abundant evidence for 
apoptosis in the thymus (158). Here, especially CD4
+, CD8
+ double positive 
thymocytes are dying. The expression of the S1P1 receptor on the surface of 
thymic endothelial cells as well as T-cells is necessary for emigration of naïve 
T-cells. However, high concentrations of S1P promote internalization of the 
S1P1 receptor and T-cells are not able to overcome the endothelial barrier 
anymore (159-160). In mice whose haematopoetic stem cells lack the S1P1 
receptor no T-cells are in the periphery because mature T-cells are unable to 
exit the thymus (160). The underlying hypothesis for this project is that apoptotic 
cells that occur in the thymus during sepsis secrete S1P thus, destroying the 
S1P gradient and promoting internalization of the S1P1 receptor, which is 
important for emigration of T-cells (lower part of Figure 39). 
 
 
 
Figure 39: Acute thymus involution as hypothetical mechanism for decreased peripheral T-cell 
count. In a healthy organism, sphingosine-1-phosphate (S1P) is highly expressed in the blood 
and lymph and rarely expressed in lymphoid tissue, such as the thymus. Naïve, mature T-cells 
follow the S1P-gradient out of the tissue into the blood/lymph. Expression of the S1P1 receptor 
(S1P1) on thymic endothelial cells as well as T-cells is necessary for emigration of naïve T-cells. 
During sepsis, thymic S1P promotes internalization of the S1P1 receptor thus, inhibiting 
emigration of naïve T-cells. 
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Targets to reduce acute thymus involution and increase emigration of naïve T-
cells are the S1P forming enzymes sphinghosine kinase (SphK) 1 and 2. By 
experiments using SphK1 and SphK2 knockout mice during sepsis, it might be 
possible to identify the responsible kinase for S1P production in the thymus. 
Furthermore, there are inhibitors for SphK1 and SphK2 available which might 
be useful therapeutic agents. Previous publications demonstrated a critical role 
of SphK1 in endotoxin signaling and sepsis-induced inflammatory responses 
and suggest that inhibition of SphK1 is a potential therapy for septic shock by 
reducing phagocyte cytokine production (161). However, they did not take the 
role of SphK1 or SphK2 during thymus involution into consideration. 
In addition, it was proposed that IL-6 is a critical mediator associated with aging 
and septic shock, and that thymic tissue can produce this cytokine (152, 162). 
On the contrary, it was shown that IL-7 and leptin protect against thymic 
remodeling during endotoxemia-induced thymus involution (150, 162-164). For 
macrophages, it was already shown that they can produce IL-6 upon S1P 
stimulation (165), leading to the following hypothesis: Sepsis induces thymocyte 
apoptosis, thereby releasing S1P and promoting thymus involution either by 
internalization of the S1P1 receptor and/or indirectly by induction of IL-6 
secretion by thymocytes. 
If the underlying hypotheses turn out to be correct, another possible target to 
improve peripheral T-cell count, besides PPAR, is identified. Targeting one of 
the S1P-producing SphKs or even S1P itselve to limit thymus involution and 
improve thymic naïve T-cell output might then further improve 
immunosuppression. The restoration of thymic function in ageing and in various 
disorders seems thus to be an important objective in the elderly, in AIDS and in 
a series of haematooncological disorders. REFERENCES     89 
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8. APPENDIX 
Phosphate buffered saline (PBS)  Upper Tris buffer (4 x) 
NaCl  137 mM  Tris/HCl  0.5 M 
KCl 2.7  mM   pH 6.8   
Na2HPO4 8.1  mM     
KH2PO4  1.5 mM  Lower Tris buffer (4 x)   
 pH 7.4   Tris/HCl  1.5  M 
      
Western Lysis buffer    SDS sample buffer (4 x)   
TRIS  50 mM  Tris/HCl  250 mM 
NaCl  150 mM  SDS  8% (w/v) 
EDTA  5 mM  Glycerol  40% (v/v) 
NP-40 0.5%  (v/v)  Bromophenol blue  0.02% (w/v) 
 pH 7.9    β-mercaptoethanol 10%  (v/v) 
Freshly added:     pH 6.8   
DTT 1  mM     
PIM 1  x  Blotting buffer   
PhosStop  1 x  Tris-HCl  25 mM 
   Glycine  192  mM 
SDS running buffer    Methanol 20%  (v/v) 
Tris/HCl 25  mM   pH 8.3   
Glycine 192  mM     
SDS   0.7  mM  TTBS   
 pH 8.3   Tween-20  0.06%  (v/v) 
    in TBS   
TBS (Tris buffered saline)    
Tris/HCl 50  mM  Neutralizing buffer for genotyping 
NaCl  140 mM  Tris-HCl  40 mM 
 pH 7.4     pH 5   
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DEPC-treated water  Lysis buffer for genotyping 
1 ml Diethylpyrocarbonate (DEPC) in  NaOH  25 mM 
1 l distilled H2O   EDTA  0.2  mM 
 stir overnight and autoclave   pH 12   
  
Urea lysis buffer    autoMACS running buffer 
Urea  6.65 M  EDTA  2 mM 
Glycerol  10% (v/v)  BSA    0.5% (w/v) 
SDS   1%  (v/v)   in PBS   
Tris-Hcl   10  mM     
deionized water  ad 50 ml  ChIP elution buffer   
 pH 7.4    NaHCO3   0.1  M 
   SDS  1%  (v/v) 
Erythrocyte lysis buffer   deionized water ad 4.5 ml 
NH4Cl 155  mM     
KHCO3   10  mM  Zinc fixative   
EDTA  0.1 mM  Tris Base  12.1 g 
   Deionized  water  900  ml 
autoMACS rinsing buffer  HCl 1.0  M 
EDTA 2  mM  Ca(C2H3O2)2   0.5 g 
 in PBS    Zn(C2H3O2)2   5.0 g 
   ZnCl2     5.0 g 
      
ChIP lysis buffer    Antibody diluent   
NaCl    150 mM  NaCl  100 mM 
Tris-HCl  50 mM  BSA  3% (m/v) 
NP-40  1% (m/v)  Triton X-100  1% (m/v) 
 pH 8.0    NaPO4   50  mM 
    pH 7.4   
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Sodium dodecyl sulfate (SDS)-polyacrylamide gel 
  10% (Separation)  4% (Stacking) 
40% Acrylamide/Bis-acrylamide 
(37.5% : 1.0% w/v) 
2.5 ml  300 µl 
Lower Tris buffer (4 x)  2.5 ml   
Upper Tris buffer (4 x)    750 µl 
H2O distilled  4.9 ml  1.95 ml 
10% SDS  100 µl  30 µl 
TEMED  10 µl  2.5 µl 
10% (w/v) ammonium persulfate  100 µl  25 µl PUBLICATIONS     109 
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